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Abstract  
 
Breast cancer remains the most common cancer among women worldwide. Although standard 
screening methods such as clinical breast examination (CBE) and Full-Field Digital 
Mammography (FFDM) are non-invasive itself, their sensitivity and specificity is limited and 
they still require biopsy proof after suspicion. Quantitative as well as qualitative changes of 
circulating cell-free nuclear and mitochondrial DNA (ccf nDNA / ccf mtDNA) have been 
shown to have potential as biomarker for breast cancer. In the first part of this study, to 
evaluate the applicability of plasma ccf nDNA and mtDNA quantitative alterations as a 
biomarker for distinguishing between three study-groups (benign, malignant, healthy), 
multiplex real-time PCR and ROC (Receiver Operating Characteristic) curve analysis were 
performed. While the levels of ccf nDNA in the cancer group were significantly higher in 
comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 
0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups 
(benign: P < 0.001; malignant: P = 0.022). Using ROC curve analysis, we were able to 
distinguish between the breast cancer cases and the healthy controls using ccf nDNA as 
marker (sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the 
healthy controls using ccf mtDNA as marker (sensitivity: 53%; specificity: 87%; P < 0.001). 
Our data suggest that both species might have a potential as biomarkers in breast tumour 
management. However, ccf nDNA seems to be the stronger biomarker regarding sensitivity 
and specificity. The second part of this work focused on finding breast cancer specific 
qualitative alterations in ccf nDNA and ccf mtDNA. Therefore MALDI-TOF MS based 40-
plex assay was applied to investigate the mutational status of candidate cancer genes (CAN-
genes) to evaluate their value as biomarker for diagnostic/therapeutic purposes. No mutations 
were found in the analyzed cell lines; only one breast cancer patient was found to be 
heterozygous at one locus within the ZFYVE26 gene which was also confirmed by single-
plex assay. Sjöblom et al. / Wood et al. already showed that the vast majority of CAN-genes 
are mutated at very low frequency. Due to the fact that we only found one mutation in our 
cohort, we therefore assume that at the selected loci, mutations might be low-frequency events 
and therefore, more rarely detectable. However, further evaluation of the CAN-gene 
mutations in larger cohorts should be the aim of further studies. Compared to nDNA, the 
analysis of mtDNA mutations has some advantages such as higher mtDNA copy numbers and 
higher mutation rate. Using Sanger sequencing we identified 43 informative mutations within 
the HVR1 and HRV2 regions in breast cancer tissues; however we did not detect these 
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mutations in mtDNA of the corresponding plasma samples.  This might be due to the fact that 
the amount of circulating mutant mtDNA is tiny in comparison to background wild-type 
mtDNA suggesting that more sensitive methods will be needed for this approach to be of 
clinical utility. Since breast cancer is frequently associated with a decrease in mtDNA content 
which we also demonstrated in the first part of this work, we finally focused on the molecular 
mechanisms that are hypothesized to underlie this decrease in mtDNA content. Therefore we 
investigated the the PGC-1 regulatory network. Reduced mRNA expression of PGC-1α and 
PGC-1β was not associated with down-regulation of target genes, such as NRF1, TFB1M and 
TFB2M. POLRMT was downregulated in breast cancer tissues what might be implicated in 
decrease in mtDNA content. PGC-1β down-regulation was neither correlated with oxidative 
DNA damage status nor with the expression of genes of the VHL/HIF-1/C-MYC-pathway. 
We suspect that PGC-1β promoter methylation might be causal for its down-regulation. 
Summing up, limited sensitivity and specificity can be considered as the bottleneck of using 
quantitative as well as qualitative alterations as marker. Overall, our data give new insight to 
the applicability of ccf nDNA and mtDNA as a biomarker for breast cancer and contribute to 
a better understanding of molecular mechanisms that are suspected to underlie quantitative 
alterations in breast cancer.  
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1. GENERAL INTRODUCTION 
 
1.1 Cancer 
In western societies cancer is the main cause of death directly following 
cardiovascular diseases. In 2008 the International Agency for Research on Cancer (IARC) 
reported 7.6 mi1lion death and 12.4 million incident cases. Estimations indicate that the 
number of individuals dying from cancer worldwide will exceed 11 million in the year 2030 
[1]. Understanding the molecular mechanisms underlying the processes of cancer initiation, 
progression and metastization could allow for finding new prevention and treatment 
strategies, thereby reducing incidence and mortality.  
In 1902 Theodore Boveri laid the foundation for modern cancer genetics, being the first to 
propose that cancer is a genetic disease that originates from a single cell which due to 
abnormal processes acquires chromosomal abnormalities that are passed on to all descendents 
of the primordial cell [2-3]. The occurrence of abnormalities in the genetic material in normal 
cells has been suspected to provide a growth advantage leading to their proliferation. As a 
consequence of genetic instability some proliferating cells might then acquire traits that 
confer a selective advantage over other cells and thereby permit clonal expansion of a 
predominant subpopulation [4]. As a consequence unrestrained growth of these cells may then 
lead to tumor formation.  
Although Boveri already postulated the existence and the importance of cell cycle 
checkpoints, oncogenes and tumor suppressor genes at the beginning of the 20th century, it 
took many years of research to get closer insight into the cellular mechanisms that drive cells 
towards malignancy and to finally be aware that carcinogenesis is not the result of a single 
event but a multistep process, an idea primarily proposed by Nordling in 1953 and revisited 
by Knudson in 1971 [5-6].  Hanahan and Weinberg recently suggested that all cancers obtain 
the same functional capabilities during the carcinogenic process. They primarily proposed six 
hallmarks cells need to acquire in order to be capable of malignant transformation: self-
sufficiency in growth signals; insensitivity to growth-inhibitory (antigrowth) signals; evasion 
of programmed cell death (apoptosis); limitless replicative potential; sustained angiogenesis 
and tissue invasion and metastasis [7]. Two novel hallmarks, namely reprogramming of 
energy metabolism and evasion of immune destruction, have evolved during the last decade 
[8] (Figure 1).  
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Figure 1: Established and emerging hallmarks of cancer. The original six hallmarks of cancer (left) have been 
complemented by two novel hallmarks (right) that have emerged during the last years as a consequence of  
remarkable progress in understanding the carcinogenic process.  Figure 1 from references [7-8]. 
 
Yet, malignant transformation could not occur without impairment of DNA damage 
signaling and deficiencies in cellular DNA repair capacity. During the evolutionary process, 
organisms developed DNA repair systems as protective mechanisms against endogenous 
(oxidative stress) and exogenous (carcinogens, viruses) threats in order to guarantee the 
maintenance of genome stability and integrity. Precise DNA repair is favourable for an 
organism in terms of propagating genetic information precisely from one to the next 
generation. On the other hand, to certain extend error-prone DNA damage repair allows an 
organism to easier adapt to physical and biological changes thereby conferring a selective 
advantage. The latter provides the basis for the expression of a mutator phenotype which in 
turn may promote the acquisition of the above mentioned hallmarks ultimately inducing 
malignant transformation [9].  
 The concept of cancer arising as a consequence of accumulation of mutations, that 
confer growth advantage to certain cells thereby leading to their clonal expansion and finally 
to malignant transformation has been questioned within the past years. Instead a theory, the so 
called cancer stem cell (CSC) hypothesis, which was already proposed 150 years ago, recently 
regained popularity [10]. It postulates the idea that cancer could arise from a distinct 
population of cells with tumor-initiating capacity.  John Dick revived the hypothesis in 1994 
by proving that human acute myeloid leukemia (AML)-initiating cells possess stem cell 
characteristics, such as the capacity to self-renew and the ability of differentiation. Using a 
murine model system Dick et al. performed transplantation experiment which revealed that 
only a subset of AML cells had the potential to initiate leukemia [11]. Since then the CSC 
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hypothesis has attracted much attention and putative cancer stem cells (CSCs) have been 
identified in a variety of cancer types. 
 
1.2 Breast cancer 
 
1.2.1 Epidemiology 
According to the World Health Organization (WHO) breast cancer is the most 
common cancer among women worldwide, accounting for nearly half a million deaths in 
2008 [12]. Although in the majority of high-income countries breast cancer incidence and 
mortality rates have been stable or even declined during the last decade due to improved 
prevention strategies [13], in low- and middle-income countries both, incidence and mortality 
have risen. A major reason for this development can be attributed to the so called 
“Westernization” of these countries, which encompasses on the one hand socioeconomic 
changes that go along with increased life expectancy and access to reproductive control and 
on the other hand adaption to western habits including dietary changes and decreased exercise 
[14]. Furthermore access to screening programs in such countries is limited, often leading to 
breast cancer diagnosis in very late stages [15].  
Risk factors of breast cancer are diverse. It has been shown that the probability of getting 
breast cancer is dependent on sex and increases with age [16], is higher in families with 
previous history of cancer or families known to be genetically susceptible to breast cancer 
(e.g. genetic alterations of BRCA1/BRCA2; TP53; ATM)[17-19] , is associated with an 
increase in certain hormone levels (e.g. estrogen, progesterone)[20] and is linked to dietary 
habits (e.g. alcohol consumption) [21] and environmental factors (e.g. carcinogens)[22].  
 
1.2.2 Definition 
The female breast is located on the anterior thoracic wall with the base extending from 
the second to the sixth rib; overlying the pectoralis major muscle of the chest, the serratus 
anterior muscle and the upper portion of the abdominal oblique muscle [23]. The breast is 
composed of glandular, adipose and connective tissue. The glandular part consists of 15 to 20 
lobes each subdivided in several lobules which are again split in clusters of milk-secreting 
sacs, the so called alveoli. A lactiferous duct drains each lobe and dilates near the nipple 
forming the lactiferous sinus [24]. Breast cancer arises from the abnormal growth of cells in 
the breast tissue. It may develop in various parts of the breast, but most frequently breast 
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cancer originates in the glandular tissue, within the lobes/lobules (milk-producing glands) and 
the milk ducts.  
 
1.2.3 Classification  
Classification of breast cancer is performed according to various criteria such as 
histopathological characteristics, stage, grade and receptor status.  
 
a. Histopathological classification 
According to histopathological appearance two major types can be discriminated, 
ductal and lobular carcinomas. Ductal carcinomas which originate from epithelial cells in the 
lumen of the mammary duct are the most common type of breast cancer. According to the 
grade of invasiveness two major pathological subtypes can be distinguished: ductal carcinoma 
in situ (DCIS) and invasive ductal carcinoma (IDC). DCIS is the most common type of non-
invasive breast cancer, accounting for approximately 20 % of screening-detected cases [25]. It 
is characterized by abnormal proliferation of epithelial cells which accumulate within the 
lumen of the mammary ducts without invading tissue beyond the epithelial basement 
membrane [26]. For this reason DCIS lacks the ability to metastasize to distant organs. 
Patients suffering from this type of cancer have been shown to have a 10-year survival rate 
close to 100%, even in the absence of treatment [27]. Nevertheless DCIS if left untreated is 
considered to be a precursor lesion to IDC; the most common type of invasive breast cancer. 
In contrast to DCIS, IDC is not confined to the mammary ducts. It invades the basement 
membrane, infiltrates into adjacent breast stroma and can metastasize to distant organs via the 
lymphatic system. Lobular carcinomas arise in the mammary lobules and terminal lobular 
ducts. Like ductal carcinomas lobular carcinomas can be divided into two major pathological 
subtypes: lobular carcinoma in situ (LCIS) and invasive lobular carcinoma (ILC). While LCIS 
is confined to the mammary lobules or lobes, ILC is invasive. ILC is the second most 
common type of invasive breast cancer and accounts for 8-14% of cases [28]. The 
aforementioned breast cancer types and other less common subtypes have been characterized 
in detail by the WHO in 2003 [29-30]. 
 
b. Classification according to the TNM-system 
The TNM-System is the most widely used system for cancer staging world-wide. It is 
based on the evaluation of the size of the primary tumor (T); the infiltration of lymph nodes 
(N) and the metastization to distant organs (M). TNM classifications are cancer type specific 
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and correspond to a certain stage (I-IV). For breast cancer, stage 0 is considered benign and 
strictly confined. Stages I-IV are defined as malignant: Stage I is characterized by a primary 
tumor size <2cm without invasion of nodes or distant organs; Stages II/III may possess a 
tumor size from <2cm to any given size with or without lymph node involvement;  Stage IV 
may have a tumor of any given size, any node status and always is of invasive nature [31].  
 
c. Histological grading 
The histological grade of the breast cancer provides information about the 
differentiation status of tumor cells under the microscope. The prognostic relevance of 
histological grading in breast cancer has been proven by various studies [32-33]. Several 
grading systems are used in practice, but most common is the Scarff-Bloom-Richardson 
grading system in which three different morphological aspects including nuclear grade, tubule 
formation and mitotic rate are evaluated. Each of the aforementioned features is assigned a 
score, ranging from 1 to 3 for each feature and ranging from 3 to 9 for all features together. 
The scores correspond to different grades. While the lowest grade corresponds to well-
differentiated tumors, the highest grade stands for a poorly differentiated tumor [34].  
 
d. Classification based on receptor status 
Classification according to receptor status including Estrogen receptor (ER), 
Progesterone receptor (PR) and Her2/neu is important in terms of prognosis and treatment of 
patients [35]. Based on receptor status, breast cancer patients can be categorized into 3 
distinct groups: i.) Hormone receptor positive: Approximately 75% of breast cancers are ER 
and around 65% are also PR positive and therefore responsive to selective modulators. ii.) 
Her2/neu positive: Merely about 20-25% of breast cancers overexpress the Her2/neu protein 
product. Her2/neu positive patients can undergo herceptin therapy, in which a recombinant 
monoclonal antibody (Trastuzumab) is directed against the receptor leading to G1 phase arrest 
and thereby to reduced cell proliferation. iii.) Hormone receptor and Her2/neu negative: 
Triple negative breast cancer occurs in around 10-17% of cases and is usually more 
aggressive and associated with poorer prognosis due to lack of targeted therapies [36-37].  
 
1.2.4 Pathophysiology  
Like other cancers, breast tumorigenesis is driven by multiple factors including 
molecular changes on the genetic, epigenetic and protein level which may affect key 
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signalling-pathways involved in cell proliferation and growth, cell-cycle control and repair of 
DNA damage.  
 
a. Genetic susceptibility 
Approximately 5-10% of breast cancers are hereditary in nature. Genetic susceptibility 
to breast cancer is due to the inheritance of genetic variants of susceptibility genes.  BRCA1 
and BRCA2 are high-penetrance cancer genes and mutations in these genes account for the 
majority of hereditary breast cancers. BRCA1/2 mutation carriers are estimated to have an 
average cumulative risk for breast cancer by the age of 70, of 65% and 45%, respectively 
[38]. Additionally, alterations in a number of genes within the p53 regulatory network have 
been linked to increased breast cancer risk. Germline mutations of p53 itself are associated 
with the Li-Fraumeni syndrome, an autosomal dominant cancer predisposition syndrome, 
characterized by the development of a variety of tumors at early onset age [39]. Association 
studies revealed that women suffering Li-Fraumeni syndrome primarily have an increased risk 
for breast cancer [40]. Other susceptibility genes include ATM [41], CHEK2 [42] and PTEN  
[43]. 
 
b. Alterations of the p53-signalling pathway 
A major signalling pathway that frequently exhibits alterations in cancer is the p53 
regulatory pathway which is induced in response to cellular stress events (DNA damage, 
hypoxia), securing the maintenance of genome stability and preventing malignant 
transformation by promoting functions in DNA repair, cell cycle arrest and apoptosis. 
Although the overall frequency of p53 mutations in breast cancer is with approximately 20% 
less than in other cancers, mutations and loss of heterozygosity (LOH) in the p53 gene are 
among the most common events in breast cancer [44-46]. In breast cancers lacking p53 
mutations, p53 is affected indirectly via diverse other mechanisms. Two important upstream 
factors of the p53 protein, the tumor suppressors phosphatase and tensin homolog (PTEN) and 
p14ARF, which protect p53 from human double minute (HDM2) ubiquitin ligase mediated 
degradation and thereby allow cells to respond to damage or mutation with an apoptotic 
response, have been found to be either mutated at a high frequency or completely lost in 
breast cancer patients [47-48]. In response to DNA damage ATM, another upstream regulator 
of p53, phosphorylates and thereby stabilizes the p53 protein directly or via a variety of 
mediators such as BRCA1 and Chk2 [49]. ATM  heterozygous are known to have an increased 
risk for developing breast cancer [50-51]. Nevertheless, increasing evidence exists that there 
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is a role for ATM in sporadic breast cancer as well.  Abnormal expression of ATM and p53 
and LOH in the region of the ATM gene located on chromosome 11q23.1 could be observed 
in sporadic breast cancer [52-53].  
 
c. Alterations of the Ras/Raf/MEK/ERK and the PI3K/AKT- signalling pathways 
Other pathways shown to be commonly altered in breast cancer include the 
Ras/Raf/MEK/ERK and the PI3K/AKT signalling pathways which regulate a variety of 
cellular processes, such as cellular growth and proliferation. The Ras/Raf/MEK/ERK cascade 
is induced by binding of growth factors to cognate receptors, which can lead to activation of 
Ras. After stimulation by activated Ras, Raf phosphorylates mitogen-activated protein kinase-
1 (MEK1), which in turn phosphorylates and thereby activates extracellular-signal-regulated 
kinases 1 and 2 (ERK1/2) whose targets include genes  involved in growth and cell cycle 
regulation such as p90 ribosomal S6 kinase (p90Rsk-1) [54] and p21 cyclin-dependent kinase 
inhibitory protein-1 (p21Cip1). On the other hand activated ERK functions through a feedback 
loop mechanism phosphorylating and regulating B-Raf, Raf-1 and MEK1. Aberrant activation 
of the Ras/Raf/MEK/ERK pathway in breast cancer has been linked to overexpression of 
growth factor receptors such as Her2/-neu and epidermal growth factor receptor (EGFR) [55-
56] and to amplification and activating mutations of Ras [57] and Raf [58].  PI3K/AKT 
pathway is initiated through stimulation of receptor tyrosine kinases (RTKs) by growth 
factors such as EGFR, Her2/-neu and IGF-1 which activate phosphatidylinositol 3-kinases 
(PI3Ks). PI3K then triggers the generation of Phosphatidylinositol (3,4,5)-triphosphate (PIP3) 
in the membrane, which functions as a second messenger and activates downstream pathways 
that involve Akt and its downstream targets [59]. Deregulation of receptor tyrosine kinases and 
of PI3K/AKT pathway genes such as activating mutations in Ras [60], in the PI3K gene [61-
62], Akt overexpression and inactivation or loss of the PTEN tumor suppressor gene [63] 
have been reported and implicated in the breast carcinogenic process. 
 
d. Alterations in mitochondrial regulatory pathways 
Alterations in mitochondrial regulatory pathways and impairment of mitochondrial 
function play a central role in cellular pathophysiology of cancer. In 1930 Warburg was the 
first realizing that cancer cells adapt to the tumor microenvironment by shifting their energy 
metabolism from oxidative phosphorylation (OXPHOS) to anaerobic glycolysis, known as the 
Warburg effect [64-65]. He hypothesized that this switch might occur as a result of impaired 
respiratory capacity. Mitochondria are the place of a variety of processes including 
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carbohydrate metabolism (TCA cycle), fatty acid oxidation, the urea cycle, gluconeogenesis, 
regulation of cytosolic NAD+, intracellular homeostasis of inorganic ions, and apoptosis [66]. 
Nowadays it is known that in cancer cells many of these processes exhibit alterations which 
are associated with cancer pathogenesis.  
Like in other cancers, in breast cancer mtDNA point mutations, deletions and insertions 
have been observed throughout the mitochondrial genome e.g. in genes coding for OXPHOS 
complexes, NADH dehydrogenase subunits and 16sRNA [67]. A mutational hot-spot is the 
D-loop region which contains regulatory elements for mtDNA replication and transcription 
[68-69]. Mutations, deletions and insertions in the D-loop have thus been linked to decreased 
expression of mtDNA encoded genes and reduced mtDNA copy number in breast cancer  
[70]. In this context, especially decrease in abundance and activities of OXPHOS complexes 
I-V is a frequent event. Owens et al. reported decreased gene expression of OXPHOS 
complexes in human breast cancer cell lines and primary tumors. They also showed 
correlation between OXPHOS defects with the severity of breast cancer [71]. Analyzes of 
protein expression levels β-subunit of F1-ATPase revealed significant down-regulation and 
expression status of β-F1-ATPase was found to be a significant marker independent from 
clinical variables to assess the prognosis of breast cancer patients [72]. Alterations of 
OXPHOS components are often associated with increased generation of ROS. Inhibition of 
electron flux within the electron transport chain is known to lead to leakage of electrons 
mainly at complexes I and III; followed by a transfer of these electrons to O2 and the 
generation of superoxide. On the one hand, there is evidence that chronically elevated 
oxidative stress together with other factors such as reduced mitochondrial membrane 
potential, increased matrix Ca2+ levels and mitochondrial permeability transition pore 
(mtPTP) induction leads to activation of apoptotic pathways; on the other hand ROS promotes 
carcinogenesis by causing mtDNA mutations, nDNA mutations in proto-oncogenes and 
tumor-suppressor genes and through driving cellular proliferation [73-74].  
A frequent alteration that has been observed in many cancer types including colorectal 
cancer [75], gastric cancer [76], renal cell carcinoma [77] and breast cancer [70] is the 
reduction of mtDNA copy number. Reduced mitochondrial DNA copy number has been 
shown to be correlated with tumor progression and prognosis in breast cancer patients and 
might therefore serve as biomarker [78]. MtDNA mutations and altered mRNA expression of 
the genes involved in mitochondrial biogenesis have been suspected to be involved in the 
reduction of mtDNA content. The network of PGC co-activators are key players in a variety 
of mitochondria-related processes including mitochondrial biogenesis [79] (Figure 2). 
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Peroxisome proliferator-activated receptor - γ coactivators PGC-1α and PGC-1β interact with 
with a wide range of transcription factors, such as ERR α, β, γ and nuclear respiratory factors 
1 and 2 (NRF-1/-2) which in turn regulate mitochondrial RNA polymerase (POLRMT), the 
mitochondrial transcription factor A (TFAM) and the dimethyladenosine transferases 1 and 2 
(TFB1M, TFB2M) . Under normal physiological conditions PGC-1 co-activators have an 
activating function in mitochondrial biogenesis. However, in cancer down-regulation of PGC-
1α and PGC-1β has been observed frequently and has therefore been suspected to play a role 
in reduction of mtDNA content [80-82]. 
 
 
 
Figure 2: The PGC-coactivator network and its function in control of mitochondrial gene expression. 
Coactivators PGC-1α, PGC-1β, PRC and RIP140 interact with DNA-binding factors ERRα PPARα, NRF-1 and 
GABPα to regulate mitochondria-related processes. DNA-binding factors regulate expression of themselves as 
well as of coregulators and target genes. Abbreviations used: BAT, brown adipose tissue; CREB, cAMP 
response element–binding protein; ERR, estrogen-related receptor; GABPα, GA-binding protein α; NRF-1, 
nuclear respiratory factor; PPAR, peroxisome proliferator–activated receptor; PGC-1, PPARγ coactivator-1; 
PRC, PGC-1-related coactivator; RIP140, receptor-interacting protein 140;WAT, white adipose tissue. Figure 2 
from reference [83]. 
 
 
1.3 Cancer Biomarkers  
1.3.1 Definition 
The Biomarkers Definitions Working Group of the US National Institute of Health’s 
(NIH) defined a biological marker (biomarker) as: “A characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, 
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or pharmacologic responses to a therapeutic intervention”[84]. Yet, until now there is no 
consensus on how the term “cancer biomarker” should be defined. If one considers the 
functions a biomarker should perform, a cancer biomarker could refer to: A biological entity 
that: i.) indicates the presence of malignancy, ii.) reflects the pathophysiological changes 
during the carcinogenic process or iii.) gives information about the response to anticancer 
therapy.  
 
1.3.2 Classification 
Regarding cancer biomarker classification, strategies are diverse.  One commonly used 
classification is performed according to a biomarkers characteristics: Thereby one can 
distinguish imaging markers such as Positron emission tomography - computed tomography   
( PET-CT), Full-Field Digital Mammography (FFDM) and Magnetic Resonance Imaging 
(MRI) and  molecular markers which are based on molecules such as DNA, RNA or Protein. 
Another popular classification scheme is based on the function a biomarker performs; one can 
for example discriminate between: prognostic (provides information regarding course of the 
disease/outcome irrespective of therapy), diagnostic (enables classification of individuals as 
diseased or non-diseased), and predictive biomarkers (assesses response to treatment)[85]. 
 
1.3.3 Current biomarkers for breast cancer 
At present less than two dozen molecular cancer biomarkers are approved by the US 
Food and Drug Administration (FDA), among which only five are breast cancer biomarkers 
such as Cancer-Antigen 15/3 (CA15-3), Cancer-Antigen 27-29 (CA27-29), Cytokeratins, 
Oestrogen and Progesterone Receptor and HER2/NEU [86]. However, these biomarkers are 
so far mostly applicable for prognosis, therapy selection and monitoring. For screening and 
early diagnosis of breast cancer, clinical breast examination (CBE) and imaging markers such 
as Full-Field Digital Mammography (FFDM) are the standard clinical procedures [87]. Even 
though all of the above mentioned breast cancer biomarkers are routinely applied in the clinic, 
they have numerous disadvantages. Firstly, many of them are invasive, as they directly 
require biopsy or at least biopsy proof after suspicion, which goes along with physical and 
psychological stress of the patients. Furthermore, especially for screening methods, sensitivity 
and specificity are quite limited. For women under the age of forty CBE is the screening 
method of choice; women over forty years of age are usually screened with a combination of 
CBE and mammography. A meta-analysis study by Barton et. al estimated overall CBE 
sensitivity at about 54% [88]. For mammography sensitivity has been reported to range from 
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85% to 90% in women over fifty years of age and has been shown to decrease to about 75% in 
women between the age of forty and fifty [89]. Regarding the false-positive detection rate, a 
ten-year retrospective cohort study estimated a cumulative risk of false positive detection up 
to 49.1 % for mammography and up to 22.3 % for CBE, considering annually screening [90]. 
This indicates the need for more sensitive and specific non-invasive biomarkers for breast 
cancer in particular for screening and early detection. 
 
1.4 Circulating cell-free nucleic acids as a potential cancer biomarker  
In the past years circulating cell-free (ccf) nucleic acids such as nuclear and 
mitochondrial DNA (nDNA /mtDNA), RNA and micro RNAs (miRs) have attracted much 
attention within the scientific community and their potential value as cancer biomarker has 
been researched widely [91-92].  
 
 
Figure 3. Cell-free nucleic acids in the circulation. Proposed release mechanisms of nucleic acids into the 
circulation by apoptosis, necrosis or active secretion (left). Quantitative (nucleic acid content) and qualitative 
(mutations, methylation, DNA integrity, microsatellite instability) alterations detectable in the circulation (right). 
Figure 3 from reference [91]. 
 
 
1.4.1 A brief history of ccf-nucleic acids   
In the first half of the 20th century, Griffith and Avery proved that DNA contains the 
hereditary information. Although at that time the underlying mechanisms of the transforming 
principle were not clear, nowadays we know that it is based on the fact that nucleic acids can 
exist in a free form in circulation and bacteria can take up foreign DNA from the environment 
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[93-94]. In 1948 Mandel and Metais for the first time detected ccf- nucleic acids in plasma of 
human beings [95]. A link between pathophysiological conditions including systemic lupus 
erythematosus, rheumatoid arthritis, leukemia, and other diseases and the amount of ccf-
nucleic acids could be made some years later [96-97]. The fact that there is an elevated ccf-
DNA concentration in the serum of cancer patients compared to normal controls was first 
observed in the late 70´s by Leon et al. [98]. Since then the biological characteristics, 
physiological/pathophysiological behaviour and the potential of quantitative and qualitative 
alterations of ccf-DNA as biomarker for cancer have been investigated widely.  
 
1.4.2 Biological characteristics and origin of ccf-DNA 
Ccf-nucleic acids refer to extracellular DNA (nuclear and mitochondrial), RNA and 
miRNA fragments floating in fluids of the human body. While in healthy individuals 
concentrations range between 0 to around 100 ng/mL, in cancer patients levels between 0 to > 
1000 ng/mL have been reported [99-100]. It has been estimated that in patients with a tumor 
of 100 g in size (≈3 × 1010 neoplastic cells), 3.3% of the tumor DNA is shed into the 
circulation daily [101]. However, this amount is usually not detectable since ccf-nucleic acid 
concentration is influenced by a variety of physiological mechanisms. Ccf-nucleic acids are 
usually cleared quite rapidly from the circulation with indicated half-lifes ranging from few 
minutes to several hours [102-103]. It is supposed that clearance of ccf-nucleic acids mainly 
takes place within liver, spleen, and kidney [104-105].  
Since the discovery of ccf-DNA the question regarding its origin remained more or less 
unanswered. There have been diverse studies pursuing this issue, mainly focusing on active 
secretion, apoptosis and necrosis. Earlier research proved that cells are able to actively release 
nucleic acids into the circulation [106-108] (Figure 3). However, growing evidence indicates 
that the major source of ccf-DNA is apoptosis and necrosis. It is supposed that as a 
consequence of high cell turnover at tumor site which is accompanied by apoptosis and/or 
necrosis, intracellular material is released from the tumor into the circulation and can thus be 
detected in blood of cancer patients [109]. Apoptosis and necrosis are morphologically and 
biochemically distinct. Apoptosis is characterised by cell shrinkage, chromatin condensation 
and DNA fragmentation which is caused by specific endonucleases, cleaving the DNA into 
nucleosomal units with about 180-200 bp. In contrast to apoptosis DNA fragments which 
result as a consequence of necrosis are much larger [107]. Earlier analyzes of ccf-DNA using 
electron microscopy and sucrose-gradient sedimentation revealed fragment sizes between 
500bp and >30 kb indicating necrotic as well as apoptotic fragments [110-111].  Using other 
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methods, some authors mainly detected small ccf-DNA fragments indicating an apoptotic 
origin [112]; others mostly reported large ccf-DNA fragments of primarily necrotic origin 
[101].  Jahr et al. found some evidence that both, apoptotic and necrotic tumor cells could be 
the source of ccf-DNA [113].  
Irrespective of its release mechanisms, the fact that elevated levels of ccf-DNA have been 
found in patients with different cancer types and the fact that this ccf-DNA features the same 
alterations than the corresponding tumor DNA demonstrates that at least a not inconsiderable 
amount of ccf-DNA is of tumoral origin. For this reason both, changes in the level of ccf-
DNA and tumor-associated alterations might have a potential as biomarker for the disease.  
 
1.4.3 Quantitative and qualitative alterations in breast cancer  
Quantitative as well as qualitative changes of ccf-DNA (ccf-nDNA and ccf-mtDNA) 
have been reported in patients with malignant and benign lesions in comparison with healthy 
individuals in various cancer types [114-119].   
Breast cancer studies on quantitative alterations were mostly performed using plasma and 
serum. In breast cancer patients plasma mean ccf-DNA levels ranged between 115 ng/mL to 
462 ng/mL; in serum mean ccf-DNA levels between 153ng/mL to 549 ng/mL could be 
observed [120].  Various studies evaluated the potential of ccf-DNA levels as diagnostic or 
prognostic marker for breast cancer. In our study we could distinguish between malignant, 
benign and healthy individuals using levels of plasma ccf-nuclear and mitochondrial DNA; 
although sensitivity and specificity was limited [115] . A potential as diagnostic marker was 
also confirmed by other groups [114, 121]. Prospective analyzes of plasma tumor DNA at 
diagnosis in breast cancer patients showed that ccf-DNA is also a valuable predictor of 
disease-free survival and may be used as a prognostic factor in these patients [122-123].  
Studies in breast cancer patients determining the concordance of tumor-specific DNA 
alterations between the primary tumor and blood mainly focused on mutations in oncogenes 
and tumor-suppressor genes, on methylation status and microsatellite alterations. Mutations in 
the p53 gene within exons 5 to 8 have been abundantly detected in tissue of primary tumor 
and in several cases could be also identified in the corresponding plasma [123-125].  Shao et 
al. showed that primary tumor and plasma DNA p53 mutations could be used as significant 
prognostic factors for both relapse-free and overall survival [126]. Methylation status of a 
variety of genes in breast tumor tissue and paired plasma or serum was also assessed in a 
subset of studies. Major analyzes were done for P16INK4A, RASSF1A, APC and BRCA1 
[127-129]. Fiegl et al. were able to use RASSF1A methylation patterns to monitor efficacy of 
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adjuvant systemic breast cancer treatment. Disappearance of RASSF1A DNA methylation in 
serum throughout treatment with tamoxifen indicated a response, whereas persistence or new 
appearance showed resistance to adjuvant tamoxifen treatment [130. Müller et al. used 
methylation status to assess the value of a set of genes (ESR1, APC, HSD17B4, HIC1, and 
RASSF1A) as prognostic markers. Patients with methylated serum DNA for RASSF1A 
and/or APC were found to have the worst prognosis [131]. Microsatellite alterations including 
allelic imbalance and LOH were analyzed as well. In many cases these markers were 
detectable in tumor tissue and circulation [132-133].  Silva et al. prospectively examined 
tumor and plasma DNA of a total of 147 breast cancer patients using six polymorphic markers 
(D17S855, D17S654, D16S421, TH(2), D10S197, and D9S161) and mutations in the TP53 
gene and demonstrated that their detection in tumor plasma DNA was a predictor of disease-
free survival [122]. The potential of both, quantitative and qualitative changes, as a biomarker 
for cancer management in general is discussed in our review [134]. 
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2. AIM OF THE WORK 
 
Quantitative alterations of ccf-nDNA and mtDNA as a breast cancer biomarker  
The discovery that tumors are capable of shedding cancer-specific nucleic acids (DNA, RNA, 
miRs) into the circulation has opened up new avenues for using these specimens as non-
invasive biomarker for cancer management. Alterations in the level of cell-free nucleic acids 
in the circulation have been observed in malignant and benign in comparison to healthy 
individuals in a variety of cancers and have therefore been suggested as biomarker for the 
disease. In the present study, to evaluate the applicability of such quantitative changes as a 
biomarker for breast cancer we raised the following questions: (1) Is there a difference in the 
amount of plasma ccf- nuclear and mitochondrial DNA between cancerous, malignant and 
healthy subjects? (2) If yes, could such quantitative alterations have a value as a non-invasive 
biomarker to distinguish between these conditions?  
 
Qualitative alterations as breast cancer biomarkers 
Various types of qualitative alterations have been observed in circulating nucleic acids and in 
many cases these alterations were also present in the primary tumor tissue of the patient. Such 
cancer-specific qualitative alterations have been proposed as a potential diagnostic tool.  
Unfortunately at present, no universal cancer-specific qualitative alterations neither for the 
disease cancer in general nor for special cancer types are available. The identification of 
qualitative alterations specific for breast cancer could permit the development of a highly 
sensitive and specific clinical approach for the management of the disease. As in our and in 
various other studies quantitative alterations of plasma ccf-nDNA and mtDNA showed a 
limited value as a biomarker due to too low sensitivity and specificity, we therefore focused 
on finding breast cancer specific qualitative alterations. In this context we developed a 
MALDI-TOF MS 40-plex assay for the detection of nuclear DNA mutations within breast 
cancer candidate genes (CAN-genes) with the aim to evaluate the value of these CAN-genes 
as a biomarker for breast cancer. Additionally, we sequenced the hypervariable regions within 
the mtDNA D-loop in 10 breast cancer patients and healthy controls with the aim to determine 
somatic mtDNA mutations within the D-loop region in breast cancer tissues and to evaluate 
whether it is possible to detect these mutations in the matched plasma samples. 
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Molecular mechanisms underlying decreased mtDNA content in breast cancer patients 
In 1926 Otto Warburg set up the theory that cancer is a disease resulting from impaired 
respiration caused by mitochondrial dysfunction. Since then various factors have been 
suspected to contribute to mitochondrial dysfunction and reduced mtDNA content in cancer 
including mtDNA mutations, deregulation of pathways involved in mitochondrial 
bioenergetics and biogenesis and increased generation of ROS. Since in our first study we 
found decreased mtDNA content in the plasma of patients with breast cancer in comparison 
with healthy controls, in the last part of this work we focused on investigating the molecular 
mechanisms that are hypothesized to underlie a decrease in mtDNA content in breast cancer 
patients. The first part aimed to investigate the intergenomic cross-talk between reduced 
mtDNA content, mtDNA mutations and methylation status of breast cancer related genes. In a 
second part we analyzed the PGC-1 regulatory network to evaluate its implication in the 
regulation of mtDNA content in cancer patients and healthy individuals. 
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3. PUBLICATIONS, MANUSCRIPTS AND PRELIMINARY DATA 
 
3.1. Published review article:                                                                                               
Cell-free DNA in the Circulation as a Potential Cancer Biomarker 
 
Authors: Corina Kohler*, Zeinab Barekati, Ramin Radpour and Xiao Yan Zhong 
 
Journal: Anticancer Res. 2011 Aug; 31(8):2623-8. 
 
Summary: Quantitative and qualitative changes of circulating cell-free nucleic acids (DNA 
and RNA) in bodily fluids have been suggested as a potential biomarker for a variety of 
cancers. However, to be applied in a clinical setting several obstacles, such as limited 
sensitivity and specificity have to be overcome. This review focuses on evaluating the 
potential of both, quantitative and qualitative changes, as a biomarker for cancer management. 
 
 
*Author contributions: Corina Kohler wrote the manuscript. 
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3.2 Published research article 1:                                                                                              
Levels of Plasma Circulating Cell Free Nuclear and Mitochondrial DNA as 
Potential Biomarkers for Breast Tumors 
 
Authors: Corina Kohler*, Ramin Radpour, Zeinab Barekati, Reza Asadollahi, Johannes 
Bitzer, Edward Wight, Nicole Bürki, Claude Diesch, Wolfgang Holzgreve and Xiao Yan 
Zhong 
 
Journal: Mol Cancer. 2009 Nov 17; 8:105. 
 
Summary: Quantitative changes of circulating cell-free (ccf) nuclear and mitochondrial DNA 
(nDNA / mtDNA) have been shown to have potential as biomarker for breast cancer. 
Multiplex real-time PCR was used to investigate the levels of ccf nDNA and mtDNA in 
plasma samples from patients with malignant and benign breast tumors, and from healthy 
controls. To evaluate the applicability of plasma ccf nDNA and mtDNA as a biomarker for 
distinguishing between the three study-groups, ROC (Receiver Operating Characteristic) 
curve analysis were performed. Our data suggest that both species might have a potential as 
biomarkers in breast tumour management. However, ccf nDNA seems to be the stronger 
biomarker regarding sensitivity and specificity. 
 
 
*Author contributions: Corina Kohler was involved in experimental design, performing the 
experiment, data analysis and writing of the manuscript. 
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3.3 Published research article 2:                                                                               
Assessing the Value of CAN-Genes using MALDI-TOF MS 
 
Authors: Corina Kohler*, Björn Tavelin, Alex Xiu-Cheng Fan, Ramin Radpour, Zeinab 
Barekati, Fabio Levi, Xiao Yan Zhong, Per Lenner and Paolo Toniolo 
  
Journal: J Cancer Res Clin Oncol. 2011 Aug; 137(8):1239-44.  
 
Summary: As in our previous study quantitative alterations of plasma ccf-nDNA and 
mtDNA showed a limited value as a biomarker due to too low sensitivity and specificity, we 
additionally focused on finding breast cancer specific qualitative alterations. Therefore 
MALDI-TOF MS based 40-plex assay was applied to investigate the mutational status of 
candidate cancer genes (CAN-genes) to evaluate their value as biomarker for 
diagnostic/therapeutic purposes. No mutations were found in the analyzed cell lines; only one 
breast cancer patient was found to be heterozygous at one locus within the ZFYVE26 gene 
which was also confirmed by single-plex assay. Sjöblom et al. / Wood et al. already showed 
that the vast majority of CAN-genes are mutated at very low frequency. We therefore assume 
that at the selected loci, mutations might be low-frequency events and therefore rarely 
detectable. However, further evaluation of the CAN-gene mutations in larger cohorts should 
be the aim of further studies. 
 
 
*Author contributions: Corina Kohler was involved in experimental design, performing the 
experiments, data analysis and writing the manuscript. 
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3.4 Published research article 3:                                                             
Mutations of Mitochondrial DNA as Potential Biomarkers in Breast Cancer  
 
 
Authors: Feng Feng Cai , Corina Kohler *, Bei Zhang , Wei Jie Chen , Zeinab Barekati, Henk 
S.P. Garritsen, Per Lenner, Toniolo Paolo, Jing Jie Zhang and Xiao Yan Zhong  
 
Summary: Compared to nDNA, the analysis of mtDNA mutations has some advantages such 
as higher mtDNA copy numbers and higher mutation rate. We used sanger sequencing with 
the aim to determine somatic mtDNA mutations within the D-loop region in breast cancer 
tissues and to evaluate whether it is possible to detect these mutations in the matched plasma 
samples. We therefore sequenced the two hypervariable regions HVR1 and HVR2, which are 
located in the D-Loop and are known as mutational hotspots in ten paired tissues and plasma 
samples from breast cancer patients. 
 
 
*Author contributions: Corina Kohler was involved in experimental design, performing the 
experiment, data analysis and writing of the manuscript. 
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3.5 Research manuscript:                                                                                   
Intergenomic Cross-Talk between Mitochondrial DNA Content, 
Mitochondrial DNA Mutations and Methylation Status of Breast Cancer 
Related Genes 
 
Authors: Corina Kohler*, Zeinab Barekati, Ramin Radpour, Alex-Xiucheng Fan, Mahdi 
Montazer Haghighi, and Xiao Yan Zhong 
 
Summary: Proper cellular function is dependent on communication between distinct cellular 
compartments. In this connection mitochondrial retrograde response plays a crucial role. 
However, under pathophysiological conditions like cancer mitochondrial to nucleus 
communication has been found to be impaired. This study investigates the inter-genomic 
crosstalk between mtDNA alterations (mtDNA content and mutations) and methylation status 
of 22 breast cancer candidate genes. We try to gain new insight in how mitochondrial 
retrograde response might be influenced by mtDNA alterations as mtDNA mutations and/or 
mtDNA copy number changes in cancer. 
 
 
*Author contributions: Corina Kohler was involved in experimental design, performing the 
experiment, data analysis and writing of the manuscript. 
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Abstract  
Background: Reduced mtDNA content, increase in mtDNA mutations and alterations in 
tumor suppressor and oncogenes have been observed frequently in patients with breast cancer. 
Within this study we therefore investigated the inter-genomic crosstalk between mtDNA 
alterations (mtDNA content and mutations) and methylation status of 22 breast cancer 
candidate genes to evaluate the impact of these factors on each other.  
Methods: Forty-five paired samples (cancerous/ paired normal breast tissues) were checked 
for mtDNA content using qPCR and for mutational status at 22 mtDNA loci using MALDI-
TOF MS. Methylation status of 22 candidate genes was compared between distinct mutational 
status groups and correlated with mtDNA content.  
Results: MtDNA content was significantly reduced in breast cancer compared to paired 
normal tissues (P=0.001). In total, 140 mtDNA sequence variants at six nucleotide positions 
were identified. No association of mtDNA content, neither with distinct mutational categories 
nor with clinicopathological parameters was found. Correlation analyzes revealed inverse 
correlation of hypermethylated TP21 and positive correlation of hypomethylated BRCA2 
(P<0.05 and P<0.05) with mtDNA content as well as inverse correlation of hypomethylated 
Progesterone receptor and positive correlation of hypermethylated GSTP1 with mtDNA 
mutations (P<0.05 and P<0.05).  
Conclusion:  This study provides closer insights into how impaired intergenomic-crosstalk 
might contribute to breast carcinogenesis. 
 
Keywords: mitochondrial DNA (mtDNA), breast cancer, MALDI-TOF MS, genotyping, 
methylation. 
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Introduction 
The hereditary information of human beings is primarily stored in the nuclear-, the 
mitochondrial- and the epigenome and alterations in each of them have been implicated with 
the carcinogenic process [135-137]. Nuclear DNA (nDNA) accounts for the majority of the 
human genetic information, represented by approximately 3 billion base pairs on 46 
chromosomes. Frequent nDNA changes linked to carcinogenesis include mutations, deletions, 
duplications and microsatellite alterations. Human mitochondrial DNA (mtDNA), however, 
represents just a minor part of the genome consisting of 16569 base pairs which encode 37 
genes involved in energy metabolism, aging and initiation of apoptosis [138]. In 1956 
Warburg hypothesised that cancer is a disease caused by mitochondrial dysfunction [139]. 
Due to close proximity to reactive oxygen species (ROS), lack of protective histone proteins 
and less efficient DNA repair mechanisms, compared to nuclear DNA (nDNA), mtDNA is 
more vulnerable to oxidative injury and has a higher level of mutation rate [140-142], 
implying its importance in pathogenesis of cancer. In contrast to the nuclear and the 
mitochondrial genome the epigenome isn’t encoded by - but can be defined as an add-on to 
the DNA sequence. Epigenetic patterns have been shown to have tremendous influence on the 
regulation of gene expression. Hypermethylation of cell cycle related genes like tumor 
suppressor genes or DNA mismatch repair genes has been shown to be a common event in 
many cancers leading to increased cell proliferation and impaired apoptosis and thereby 
driving tumorigenesis [143].  
Although the nuclear and mitochondrial genomes are spatially separated, 
mitochondrial and nuclear functions are bidirectionally linked through i) anterograde 
regulation where the information-flow is directed from nucleus towards mitochondria, and ii) 
retrograde regulation which is defined by the reverse condition, in which nuclear gene 
expression is influenced by mitochondrial signals [144]. Under pathophysiological conditions 
like cancer mitochondrial retrograde response might be influenced by mtDNA alterations as 
mtDNA mutations and/or mtDNA copy number changes potentially lead to impairment of 
mitochondrial to nucleus communication. Indeed, mtDNA mutations found in the D-Loop and 
near the replication origin of the heavy-strand have been shown to decrease mtDNA copy 
number [78, 145] and in turn, mtDNA copy number reduction has been implicated with 
altered nuclear DNA methylation. Smiraglia et al demonstrated that mitochondria depleted 
rho0 cell-lines exhibit a significant degree of aberrant CpG-island methylation compared to 
their parental cell-lines [146]. Xie et al. showed that loss or reduction of mitochondrial DNA 
results in the induction of DNA methyltransferase-1 and in hypermethylation of the promoters 
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of  several nuclear genes including endothelin B receptor, O6-methylguanine-DNA 
methyltransferase, and E-cadherin [147]. These findings suggest that mtDNA mutations, 
mitochondrial DNA copy number and nuclear DNA methylation are not independent from 
each other; instead it appears that they interact in a complex network.  
To address this hypothesis we performed a correlation study using a cohort of 45 
breast cancer patients. Correlation between mitochondrial DNA content, mitochondrial DNA 
mutations (located in D-Loop, 12SrRNA, 16SrRNA)  and methylation status of 22 breast 
cancer candidate genes (APC, BIN1, BMP6, BRCA1, BRCA2, CADHERIN1, CST6, DAPK1, 
EGFR, ESR2, GSTP1, NES1, Nm23-H1, P16, P21, Progesterone receptor, Prostasin, RAR-b, 
RASSF1, SRBC, TIMP3 and TP53) was assessed using quantitative PCR and matrix-assisted 
laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF).  
 
Materials and Methods 
Tissue Samples  
The study was approved by the local ethical committee and department of pathology, 
Shahid Betheshi Medical University, Iran. Forty-five paired formalin-fixed paraffin-
embedded samples from cancerous breast tissues and paired normal breast tissues were 
examined by two experienced pathologists. Clinical data of patients can be obtained from 
Table 1. DNA was extracted from paraffin-embedded samples (around 20 mg of tissue) using 
a High Pure PCR Template Preparation Kit (Roche Diagnostics, Mannheim, Germany) 
according to the manufacturer’s protocol and eluted into 150 µL of elution buffer. The eluted 
DNA was stored at -20°C until further use.  
 
Cell culture  
MDA-MB-231, MCF-7, and HS578T cells were grown in Dulbecco’s modified Eagle 
medium (DMEM) (4.5g/l glucose L-glutamine); BT549 and T47D cells were grown in RPMI 
1640 (L-glutamine); SKBR3 cells were grown in McCoy’s 5A medium. All media purchased 
from Gibco/Invitrogen (Carlsbad, CA, USA) were supplemented 10% FCS and 1% penicillin-
streptomycin. The cells were maintained in a humified incubator at 37°C 5% CO2, and 
harvested at 80% confluency. Before DNA extraction the cells were washed 1xPBS. DNA 
was extracted from 1x106 cells by using the High Pure PCR Template Preparation Kit (Roche 
Diagnostics, Mannheim, Germany) and eluted in 100 µL of elution buffer and stored at -20°C 
until further use. 
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Quantitative analysis of mtDNA using Real-time PCR 
For simultaneous quantification of nDNA and mtDNA a multiplex TaqMan real-time 
PCR was performed using both Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mitochondrial ATPase subunit 8 (MTATP 8) reference genes. The GAPDH and MTATP 8 
primer and probe sequence information is shown in Supplementary Data 1 (Table 1). The 
PCR was performed using the ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems, Branchburg, New Jersey, USA). 2.5 µL DNA were used as template for the PCR 
analysis. The real-time PCR was carried out in 25 µL of total reaction volume using a 2 
minute incubation at 50°C, followed by an initial denaturation step at 95°C for 10 minutes and 
40 cycles of one minute at 60°C and 15 seconds at 95°C. 
The theory, practice, the amplification efficiency and results of quantitative PCR for 
both GAPDH and MTATP 8 has been demonstrated in our previous study [148] and 
information about how data were processed can be retained from Kohler et al. 2009 [115].  
 
Assay design for qualitative analyses of mtDNA variants 
  Based on the Cambridge Reference Sequence (CRS) of the human mitochondrial 
genome and the publication of Zhu et al (2005)[149], in total 45 loci were selected as input 
for the assay design. Due to the compromise of amplicon length, primer length and the mass 
range, and to reduce primer-dimer potential and false priming potential, 22 somatic mutations 
were selected for further analysis. Of these 22 somatic mutations, three were located in D-
Loop, one in 12S ribosomal RNA, one in 16S ribosomal RNA, two in tRNA, 11 in NADH 
dehydrogenase subunits, one in ATPase subunit 8, one in Cytochrome C oxidase subunite III, 
and one in cytochrome b region. Detailed information about the location of the analyzed loci 
can be obtained from Figure 1 and Supplementary Data 1 (Table2). 
 
Iplex-assay for the detection of mtDNA variants 
For each variant, two primers for amplifying the product containing the variant 
(capture primers) and one primer for extending each variant (extension primer) were designed 
using MassArray Assay Design v.3.1 (Sequenom, San Diego, USA). Sequence information of 
SNP capture and extension primers are shown in Supplementary Data 1 (Table 2). According 
to the manufacture’s protocol a 10-mer tag (5’-ACGTTGGATG-3’) was added to the 5’end of 
each primer to avoid chaos in mass spectrum and improve PCR efficiency. 
The SNP capture PCR reactions for amplifying 22 fragments containing the 22 
sequence variants in a single well were carried out in 10 µL PCR cocktail mix containing 1µL 
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DNA, 1.626 mM MgCl2, 500 µM dNTP mix, 0.5 U HotStarTaq DNA polymerase and primer 
pairs. The amplification was performed under the following conditions: incubation at 94°C 
for 15 minutes, followed by 45 cycles of 94°C for 20 seconds, 56°C for 30 seconds, 72°C for 
one minute and final extension at 72°C for 5 min. To remove the non-incorporated dNTPs, a 
shrimp alkaline phosphatase (SAP) treatment was performed after the PCR reaction under the 
following conditions: 37°C for 20 minutes, 85°C for 5 minutes and cooling to 4°C. The 
iPLEX extension reaction was performed using the iPLEX gold cocktail mix (Sequenom, San 
Diego, USA), which contains buffer, termination mix, enzyme and extension primers, under 
the following conditions: 94° C for 30 seconds, followed by 40 cycles of 94°C for 5 seconds, 
plus 5 sub-cycles of 52°C for 5 seconds and 80°C for 5 seconds; one cycle of final extension 
at 72°C for 5 min, then cooling to 4°C. The iPLEX reaction products were desalted using 
clean resin to optimise mass spectrometric analysis and dispensed onto a 384-element 
SpectroCHIP bioarray by using a nanodispenser (Sequeonom, San Diego, USA) for MALDI-
TOF MS analysis. The MassARRAY 4.0 software (Sequeonom, San Diego, USA) was used 
to process and analyze iPLEX SpectroCHIP bioarrays. The call rate, extension rate and peak 
area for all allele-specific analyses in any given assay were calculated using the software 
provided by the manufacturer. DNA from a mitochondria negative cell line, which was 
obtained by sub-culturing that cell line in the presence of low concentration of ethidium 
bromide until the cells were devoid any of mitochondria, was used as control. The negative 
control was run at each step and on each chip. 
 
Methylation analysis using thymidine-specific cleavage MassArray® on MALDI-TOF 
MS 
In a previous study we used high-throughput analysis to determine DNA methylation 
patterns of 22 candidate cancer gene promoters (APC, BIN1, BMP6, BRCA1, BRCA2, 
CADHERIN1, CST6, DAPK1, EGFR, ESR2, GSTP1, NES1, Nm23-H1, P16, P21, 
Progesterone receptor, Prostasin, RAR-b, RASSF1, SRBC, TIMP3 and TP53)  in the breast 
cancer and paired normal tissue samples [150]. Sequenom`s EpiTYPER™ assay in 
combination with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) and MassCLEAVETM reagent was performed according to the previously 
published protocols [150-152]. Epitect® Bisulfite Kit (QIAGEN AG, Basel, Switzerland) was 
used for the conversion of the target sequence, followed by PCR and in vitro transcription. 
For final analyzes the product was robotically dispensed (nanodispenser) onto silico chips 
preloaded with matrix (SpectroCHIP; SEQUENOM, San Diego) and analyzed in a mass 
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spectrometer (MALDI-TOF MS). Mass spectra were collected using a MassARRAY 
Compact MALDI-TOF (SEQUENOM) and spectra’s methylation ratios were generated by 
the Epityper software v1.0 (SEQUENOM, San Diego). 
 
Statistical analysis 
Data were analyzed using SPSS 17.0 (SPSS Inc., Chicago, USA). The Shapiro-Wilk 
test was used for the analysis of data distribution. The data were not normally distributed. The 
Mann–Whitney-U test and Kruskal–Wallis test were applied to compare the mtDNA content 
between individuals with different mutation status/categories and tissue types.  Pearson chi-
square test was applied to analyze the association between mtDNA variants and 
clinicopathological parameters as well as the association between tissue types and 
clinicopathological parameters.  
For gene clustering, pair-wise similarity metrics were calculated for each gene 
separately based on methylation ratio of cancer tissues across the paired paired normal tissues. 
The procedure was performed using the double dendrogram function of the Gene Expression 
Statistical System for Microarrays (GESS) version 7.1.19 (NCSS, Kaysville, Utah, 
USA)[150-152]. To evaluate whether there is a correlation between mtDNA mutations and 
mtDNA content with percentage of promoter methylation of the 22 candidate cancer genes a 
Spearman`s rho correlation was performed. For all analysis P-values ≤ 0, 05 were considered 
statistically significant. 
Results 
Comparison of mtDNA content between cancerous and paired normal tissue 
MtDNA content in cancerous tissues was significantly reduced compared to paired 
normal tissue (Mann-Whitney: P=0.001) (Figure 2A). MtDNA contents in cell lines were 
1478.58, 809.00, 3350.13, 3040.30, 910.18, and 2.89-fold high in BT549, HS578T, T47D, 
SKBR3, MCF-7, and MDA-MB231 cells, respectively.  
 
Simultaneous analysis of 22 mitochondrial loci using the MALDI-TOF MS based 22-
plex assay 
Using the MALDI-TOF MS 22-plex assay, we examined 22 mtDNA loci in 45 
cancerous and paired normal tissue samples, as well as in 6 breast cancer cell lines. In total 
140 sequence variants at 6 nucleotide positions were found, thereof 130 in tissue samples and 
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10 in breast cancer cell lines; two were located in D-loop, one in 12S RNA, one in 16S RNA, 
and one in tRNA- threonine (Table 2). The location of the variants analyzed and mass spectra 
of detected variants and their corresponding wild-types in tissue samples are shown in Figure 
1.  
 
Association between mtDNA variants and clinicopathological parameters 
 Furthermore we compared clinicopathological parameters with mtDNA content 
between variant positive and negative individuals in cancerous and normal tissues.  In this 
study we did not find mtDNA content in cancerous and normal tissues was associated with 
age, tumour type, tumour size, lymph node involvement, extent of metastasis, stage, 
histological grading, and ER, PR, and HER-2/neu receptors of neither variant positive nor 
negative individuals (Supplementary 2, Table 1). 
 
Relation between mtDNA content and mtDNA mutations 
Comparison of mtDNA content between mutation negative and mutation positive 
individuals within the cancerous, the paired normal group and within both groups combined 
showed no significant difference (Mann-Whitney: P=0.475 and Mann-Whitney: P=0.163). 
For analyzing the relation between mtDNA content and different mtDNA mutation categories 
we divided the individuals in 3 groups according to their mutational status: individuals 
carrying somatic mutations (mutation either present in cancerous or normal tissue); 
individuals carrying germline mutations (mutations present in cancerous and paired normal 
tissue); individuals without mutations. No significant difference could be found between the 
mtDNA content of individuals carrying somatic mutations, individuals carrying germline 
mutations and individuals without mutations (Kruskal-Wallis: P=0.311).  
Correlation of mtDNA content and mtDNA mutations with methylation status of 22 
candidate breast cancer genes 
Two-way hierarchical cluster analysis comparing the methylation status in cancerous 
and paired normal tissue is shown in Figure 2B. We correlated mtDNA content and mtDNA 
mutations with the percentage of methylation of 22 candidate breast cancer genes. We found 
significant positive correlation between mtDNA content and the percentage of methylation for 
BRCA2 (P<0.05; R=0.477), and significant negative correlation between the same parameters 
for TP21 (P<0.05; R= -0.582) in cancerous tissues (Figure 2C). Between mtDNA mutations 
and percentage of methylation there was a positive correlation for GSTP1 (P<0.05; R=0.489) 
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and a negative correlation for Progesterone receptor (P<0.05; R=-0.567) in cancerous 
tissues; whereas we found positive correlation for TIMP3 (P<0.01; R=0.579) in the 
corresponding normal tissue. For comparing nDNA methylation status within different 
mtDNA mutation categories we divided the individuals in 3 groups as previously described. 
Significant difference in the methylation status was found only for the progesterone receptor 
gene (Kruskal-Wallis: P<0.05) in cancerous tissues (Figure 2D).  
 
Discussion 
Proper cellular function requires a tight interplay between distinct cellular 
compartments. In this regard mitochondria-to-nucleus retrograde and nucleus-to-mitochondria 
anterograde signaling plays an important role. Defects in this inter-genomic communication 
can result in altered cell metabolism and aberrant signalling, triggering carcinogenesis. 
Mutations in nuclear DNA are thought to lead to disruption of the normal cross-talk that 
regulates the integrity and quantity of mtDNA [153]. On the contrary depletion of mtDNA 
was shown to regulate nuclear cancer associated genes and to lead to chromosomal instability 
[147, 154-155]. To get better insight in the underling mechanisms that drive carcinogenesis in 
an intergenomic manner we investigated the correlation between mtDNA content, the 
mutational status of 22 mtDNA loci and methylation of 22 candidate genes in 45 breast cancer 
and corresponding normal tissues.  
Significantly reduced mtDNA content in cancerous tissue compared to paired normal 
tissue has been reported in previous studies [78]. It has been hypothesized that mutations in 
the displacement-loop (D-Loop), a region containing the origin of replication of the H-strand 
and the promoters for L- and H-strand transcription, might lead to impaired transcription and 
replication and finally to depletion of mtDNA. Indeed, there is evidence that mtDNA 
depletion is correlated with the presence of somatic mtDNA mutations [70, 145]. Therefore 
we analyzed loci located in D-Loop, 12S rRNA, 16S rRNA and tRNA-T and correlated 
mutational status with mtDNA content. Although five of the six sequence variations have 
been reported previously as polymorphisms in Mitomap, some of the variations we only 
found in the patient but not in the corresponding normal sample, suggesting that in these 
patients the variant is of somatic character. Loci which were reported as polymorphisms but 
also showed somatic mutations at the same position include: 709G>A; 15924A>G; 
16145G>A. As the studied population might be heterogenous and composed of a variety of 
haplogroups, there is the possibility that sequence variants can be highly abundant in one 
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haplogroup, and occur as somatic mutation in another haplogroup. Although we found 
significantly reduced mtDNA content in cancerous tissue compared to normal paired tissue 
(P=0.001), we couldn`t find a correlation with neither somatic mtDNA mutations nor with 
clinicopathological parameters.   
Performing correlation studies we found inverse correlation between mtDNA content 
of variant positive individuals with hypermethylation of the TP21 and positive correlation 
with hypomethylation of BRCA2 gene. P21 is a cyclin-dependent kinase (cdk) inhibitor, 
known to inhibit the activity of cyclin/cdk2 complexes and thereby negatively modulate cell 
cycle progression. Hypermethylation of TP21 promoter might therefore result in 
transcriptional repression and promotion of cell cycle progression leading to a proliferative 
phenotype. Although there has been no report of a direct effect of p21 loss on mtDNA 
depletion, there might be an indirect effect via p53, since p21 is a transcriptional target of p53 
[156]. In breast cancer p53-transactivation of TP21 is frequently impaired due to p53 
inactivation [157].  In turn loss of p53 is known to mediate depletion of mtDNA by down 
regulating p53R2 [158-159]. On the other hand p21 is also an inhibitor of apoptosis and p21 
repression may therefore have an anticancer effect [160]. Schauen et al. found that respiratory 
chain deficiency slows down cell-cycle progression via reduction of ROS which also was 
associated with downregulation of p21CIP1/WAF1 in mitochondria deficient ρ0-cells [161].  
Although BRCA2 gene promoter hypomethylation has been shown to correlate with 
elevated levels of BRCA2 mRNA and tumor stage there is no previous report on how BRCA2 
expression might influence alteration of mtDNA content and reverse. Hypermethylation of 
Glutathione S-transferase π (GSTP1) was positively correlated and hypermethylation of 
Progesterone receptor (PGR) was inversly correlated with mtDNA mutations. It is known 
that Glutathione S-transferases, the enzymatic products of the GSTP1 gene play an important 
role in the protection of DNA from oxidative damage [162] and that loss of GSTP1 due to 
promoter hypermethylation is a common event in prostate and breast carcinogenesis [163-
164]. Yet, there is no evidence that this promoter hypermethylation might be associated with 
mutations in mtDNA. Although hypermethylation of estrogen and progesterone receptor gene 
5' CpG islands have been found to be correlated with lack of estrogen and progesterone 
receptor gene expression in breast tumors [165], very few studies analyzed the relationship 
between progesterone receptor expression and mtDNA mutations. Only Tseng et al reported 
that the occurrence of D-Loop mutations in mitochondria of breast cancer patients was 
associated with tumors that lacked expressions of estrogen receptor and progesterone receptor 
[70]. This is in concordance to our data and remains to be further evaluated.   
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To get a detailed insight into the mechanisms leading to impairment of intergenomic 
cross-talk between mitochondria and nucleus in breast cancer we analyzed the interplay of 
mtDNA content, mtDNA mutations and methylation status of 22 candidate breast cancer 
genes. Regarding mtDNA content in cancerous tissues our data confirm the results of 
previous studies which also found mtDNA depletion in cancerous compared to normal 
patients. Although we couldn’t find a correlation between mtDNA depletion and somatic 
mutations we have indication that in this cohort mtDNA depletion might be associated with 
loss of p21 expression either due to direct inhibition via TP21 hypermethylation or as 
consequence of impaired p53-transactivation due to loss of p53. However, we cannot exclude 
the possibility that mtDNA depletion is caused by a completely different mechanism. In total, 
our data provide some insight in how and by which factors intergenomic cross-talk might be 
deregulated in breast cancer patients. Decrypting these complex intergenomic mechanisms 
between nucleus and mitochondria in larger cohorts should be the aim of further studies. 
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Tables and table headings 
 
Table 1. Clinical data of patients according to 2 different breast cancer types. 
 
Breast cancer 
type 
Total 
no.       
of 
patients 
Age (years)         
(mean ± s.d. 
[range])  
Tumor size 
(cm)        
(mean ± s.d. 
[range]) 
No. of 
patients 
with lymph 
node 
involvement 
No. of 
patients 
with 
metastasis 
ER 
status 
PR 
status 
pos neg pos Neg 
Infiltrating 
ductal 
carcinoma 
37 49± 11.45  [32-78] 
3.0 ± 2.6   
[0.8-12] 31 8 11 26 14 23 
Infiltrating 
lobular 
carcinoma 
8 46 ± 11.9   [32-65] 
2.6 ± 1.7   
[1.5-4.5] 5 1 1 7 1 7 
 
 
Table 2. Mutation frequencies of variant positive mtDNA loci. mtDNA sequence variants 
were present at six out of 22 nucleotide positions in 45 paired breast/normal tissues and six 
breast cancer cell lines. Variation positive mtDNA loci have been found in D-loop 
(displacement-loop); 12S (12S ribosomal RNA); 16S (16S ribosomal RNA); tRNA-T (tRNA 
threonine) genes. 
Gene Gene ID 
Nucleotide 
position/ 
modification 
Number of times detected  Frequency (%) 
Germline Somatic (Cancer/Normal) 
Cell 
line Germline Somatic Cellline 
D-
Loop − 
311-315 - 
>Cins 44 0 6 97.7 0.0 100.0 
12S 4549 709G>A 6 (1/0) 1 13.3 (2.2/0) 2.2 
16S 4550 2706A>G 4 0 3 8.8 0.0 50.0 
tRNAT 4576 15924A>G 2 (2/0) 0 4.4 (4.4/0) 0.0 
D-
Loop − 16145G>AG 0 (0/3) 0 0.0 (0/6.7) 0.0 
D-
Loop − 16145G>A 6 (2/2) 0 13.3 (4.4/4.4) 0.0 
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Figures and figure legends 
 
 
Figure1. Schematic illustration of mtDNA structure with positions of 22 analyzed mtDNA 
loci and MALDI-TOF MS spectrograms of the six variants detected.  The mtDNA structure 
shows the 37 genes including 13 protein encoding genes, 22 tRNAs (black bars) and 2 
rRNAs. Grey filled circles represent loci where no variant was found; Black filled rhombs 
represent germline mutations; white filled rhombs represent somatic mutations. Numbers on 
the right side of symbols indicate frequency of occurrence. MALDI-TOF spectrograms for 
each detected mutation (M) and the corresponding wild-type (WT) are depicted. Similar 
colored dashed lines represent the unextended primers (UEP) and the respective wild-type 
alleles.  
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Figure2. A.) Boxplot for comparison of mtDNA content between paired cancer and normal 
breast tissues. (significant: Mann-Whitney-U; P < 0.001). B.) Methylation analysis of 
informative CpG sites for the five genes that showed correlation of percentage of methylation 
with either mtDNA content or mutational status. Two-way hierarchical cluster analysis of 45 
cancerous breast and corresponding normal tissues (red clusters indicate 0% methylated; 
yellow clusters indicate 100% methylated; color gradient between red and yellow indicates 
methylation ranging from 0 to 100). C.) Correlation of mtDNA content with percentage of 
methylation for significant genes (BRCA2/P21). D.) Boxplot for comparison of percentage of 
methylation within different mutational status groups for Progesterone receptor (significant: 
Kruskal-Wallis: P<0.05). 
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Supplementary Data 1 
 
Supplementary Table 1. Primer and probe sequence information for GAPDH and MTATP 8  
reference genes used for simultaneous quantification of nDNA and mtDNA by multiplex 
TaqMan real-time PCR. 
 
Gene  Gene ID Primer and Probe Sequences (5`→3`) 
Length of 
primer/ 
probe 
Amplicon 
lengths (bp) 
GAPDH 2597 
Forward CCC CAC ACA CAT GCA CTT ACC 21 
97 Reverse CCT AGT CCC AGG GCT TTG ATT 21 
Probe (MGB) TAG GAA GGA CAG GCA AC (VIC)  17 
MTATP8 4509 
Forward AAT ATT AAA CAC AAA CTA CCA CCT ACC  27 
78 Reverse TGG TTC TCA GGG TTT GTT ATA  21 
Probe (MGB) CCT CAC CAA AGC CCA TA (FAM) 17 
 
 
Supplementary Table 2. Gene, gene ID, nucleotide positions of analyzed loci and sequence 
information of SNP capture and extension primers used for MALDI-TOF MS 22-plex 
mtDNA mutation assay. 
 
Gene Gene ID 
Nucleotide 
position 
(np) 
Mutation capture primer Extension primer 
D-
Loop - 207 
ACGTTGGATGTTACAGGCGAACATACTTAC 
TACATGCGAACATACTTACTAAAGTGT 
ACGTTGGATGAAGTGGCTGTGCAGACATTC 
D-
Loop - 311-315 
ACGTTGGATGAAATTTCCACCAAACCCCCC 
CAAACCCCCCCTCCCCC 
ACGTTGGATGGCTGGTGTTAGGGTTCTTTG 
12S 4549 709 
ACGTTGGATGAGGTTTGGTCCTAGCCTTTC 
GGGTGAACTCACTGGAA 
ACGTTGGATGTCGTGGTGATTTAGAGGGTG 
16S 4550 2706 
ACGTTGGATGAGGGTTCAGCTGTCTCTTAC 
GTTATTCTCGTCTTGCTGTGT 
ACGTTGGATGCATAGGGTCTTCTCGTCTTG 
ND1 4535 3849 
ACGTTGGATGACACCTCTGATTACTCCTGC 
TCCTGCCATCATGACCCTT 
ACGTTGGATGTCGGTTGGTCTCTGCTAGTG 
tRNA-I 4565 4323 
ACGTTGGATGCCCTCAAACCTAAGAAATATG 
CCCCATAGGAGCTTAAACCCCC 
ACGTTGGATGGGTTCGATTCTCATAGTCCT 
ND2 4536 4499 
ACGTTGGATGTGTTGGTTATACCCTTCCCG 
GCCCAACCCGTCATCTA 
ACGTTGGATGTGATGAGTGTGCCTGCAAAG 
ND2 4536 4665 
ACGTTGGATGCATCAAGTATTTCCTCACGC 
TCCTCACGCAAGCAACC 
ACGTTGGATGATGGTTCATTGTCCGGAGAG 
ND2 4536 5240 
ACGTTGGATGCTTAATTCCATCCACCCTCC 
GATTTGGGCAAAAAGCCGGT 
ACGTTGGATGCTTCGATAATGGCCCATTTG 
ATP8 4509 8498 
ACGTTGGATGCACAAACTACCACCTACCTC 
GGTTCTCAGGGTTTGTTATAATTTT 
ACGTTGGATGCGTTCATTTTGGTTCTCAGG 
COXIII 4514 9885 ACGTTGGATGTATCTGCTTCATCCGCCAAC TCCGCCAACTAATATTTCAC 
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ACGTTGGATGAAAATGCCAGTATCAGGCGG 
ND4 4538 11768 
ACGTTGGATGCGGGCTTACATCCTCATTAC 
GGGCACTCAAACTACGAACGC 
ACGTTGGATGTGAGAGAGGATTATGATGCG 
ND5 4540 12642 
ACGTTGGATGCATCCCTGTAGCATTGTTCG 
GAGTTACATGGTCCATCATAGA 
ACGTTGGATGGATTAATGTTTGGGTCTGAG 
ND5 4540 12852 
ACGTTGGATGATCAGTTGATGATACGCCCG 
TTCTCAGCAGCCATTCAAGCAAT 
ACGTTGGATGGAAACCGATATCGCCGATAC 
ND5 4540 13263 
ACGTTGGATGATCGTAGCCTTCTCCACTTC 
TTATTGTAACTATTATGAGTCCTAG 
ACGTTGGATGAGGAATGCTAGGTGTGGTTG 
ND5 4540 13398 
ACGTTGGATGCTATTTATGTGCTCCGGGTC 
ACAACCTTAACAATGAACA 
ACGTTGGATGGGTTGAAGTGAGAGGTATGG 
ND5 4540 13674 
ACGTTGGATGGCTTCCCCACCCTTACTAAC 
CCCCCCTTACTAACATTAACGAAAA 
ACGTTGGATGAATCCTGCGAATAGGCTTCC 
ND5 4540 15700 
ACGTTGGATGTCCCCATCCTCCATATATCC 
GAGTGATTGGCTTAGTGG 
ACGTTGGATGGCGGCTAGGAGTCAATAAAG 
CYTB 4519 15783 
ACGTTGGATGGCAGACCTCCTCATTCTAAC 
GACAACCAGTAAGCTACC 
ACGTTGGATGCGGATGCTACTTGTCCAATG 
CYTB 4519 15824 
ACGTTGGATGCATTGGACAAGTAGCATCCG 
CCTCAGCATCCGTACTATACTTC 
ACGTTGGATGGGGAGATAGTTGGTATTAGG 
tRNA-
T 4576 15924 
ACGTTGGATGAAATGGGCCTGTCCTTGTAG 
ACACTAATACACCAGTCTTGTAA 
ACGTTGGATGTTTCTCTGATTTGTCCTTGG 
D-
Loop  16145 
ACGTTGGATGGCCAGCCACCATGAATATTG 
TATTGTACGGTACCATAAATACTT 
ACGTTGGATGGGGTTTTGATGTGGATTGGG 
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Supplementary Data 2 
 
Table 1. Comparison of clinicopathological parameters with mtDNA content between variant 
positive and negative individuals in cancerous and paired normal tissues. 
 
 
 
 
 
 
 
Clinico-
pathological 
parameters 
Sub-
classification 
n 
(paired) 
mtDNA content 
(Cancerous)       
Median   
P-value 
mtDNA content 
(Normal)           
Median  
P-value 
With 
variant  
Without 
variant 
With 
variant  
Without 
variant 
Age  
< 50 27 15.77 5.8 0.548 119.44 50.39 0.576 
≥ 50 18 4.98 3.38 188.5 60.38 
Histological 
type 
Ductal 38 9.88 3.63 0.782 30.91 50.39 0.791 Lobular 7 5.76 5.7 216.02 352.46 
Primary tumor 
T1 20 19.23 6.32 
0.372 
21.86 66.95 
0.39 T2 14 6.92 2.98 30.91 53.82 
T3 7 5.76 7.9 823.14 37.67 
Lymph node 
involment 
Negative 7 17.87 1.53 0.684 108.04 106.15 0.828 Positive 37 5.76 5.8 30.91 53.82 
Metastasis 
M0 37 12.45 5.8 0.747 123.46 66.95 0.81 M1 7 3.6 3.11 211.82 53.82 
Stage 
I 5 17.87 1.19 
0.87 
108.04 9.48 
0.394 
II 24 6.43 5.6 18.96 66.95 
III 6 10.19 - 584.61 - 
IV 6 6.92 3.11 420.22 53.82 
Nuclear grading 
1 3 24.25 3.75 
0.18 
1406.29 7.3 
0.159 2 11 3.59 10.08 184.47 96.37 
3 15 1.59 2.98 10.48 49.35 
ER 
Negative 12 2.98 3.4 0.575 16.06 49.35 0.067 Positive 17 9.88 15.13 823.14 572.56 
PR 
Negative 12 1.56 3.11 0.208 7.31 49.35 0.235 Positive 17 9.88 16.43 823.14 79.98 
Her2 
Negative 12 12.45 3.11 0.171 665.8 106.15 0.398 Positive 17 2.98 16.43 16.06 52.1 
P53 
Negative 26 6.34 3.63 0.52 26.38 50.39 0.54 Positive 3 15.03 1.55 2304.13 106.15 
PS2 
Negative 18 8.4 3.51 
0.93 
26.38 52.1 
0.723 Positive 10 10.39 26.63 665.8 106.15 
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Figure 1. Comparison of nDNA methylation status within 3 different mtDNA mutation 
categories (somatic; germline; variant-) for non-significant genes. 
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Figure 2 . Correlation of nDNA methylation status with mtDNA content per cell for non-
significant genes.  
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3.6 Preliminary data:                                                                                       
The PGC Regulatory Network and its Implication in Decreased MtDNA 
Content in Breast Cancer 
 
Summary: In our previous study analyzing the inter-genomic cross-talk between mtDNA 
alterations and methylation of nuclear encoded genes, we could not find a meaningful 
correlation between mitochondrial DNA content, mitochondrial DNA mutations and 
methylation status of breast cancer related genes. In cancer, reduction of mtDNA content and 
mitochondrial dysfunction has also been associated with oxidative stress, deregulation of 
PGC-1 co-activators and their target genes. Within this study we investigated the PGC-1 
regulatory network of to evaluate its role in the regulation of mtDNA content in breast cancer. 
 
 
*Author contributions: Corina Kohler was involved in experimental design, performing the 
experiment, data analysis and writing of the manuscript 
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Abstract 
Background: In cancer, reduction of mtDNA content and mitochondrial dysfunction has 
been associated with oxidative stress, deregulation of PGC-1 co-activators and their target 
genes. Within this study we investigated the PGC-1 regulatory network of to evaluate its role 
in the regulation of mtDNA content in breast cancer.   
Methods: Thirty paired samples (breast cancer and adjacent normal tissues) were checked for 
mtDNA content, mRNA expression of PGC-1α and PGC-1β and their target genes using 
Taqman quantitative real time PCR. Hypoxic status and oxidative DNA damage were 
assessed by HIF-1α expression and ARP-assay, respectively. Methylation analysis of PGC-1β 
promoter region will be performed using pyrosequencing. 
Results: MtDNA content in cancer tissues was significantly lower in comparison with paired 
normal tissues (P < 0.001). PGC-1β was significantly down-regulated (P<0.05). While NRF1, 
TFB1M and TFB2M (P<0.05; respectively) showed significant up-regulation, POLRMT was, 
also if not significantly, down-regulated in cancer tissues. HIF-1α mRNA expression and 
oxidative DNA damage was higher in cancer than in normal tissues. No correlation was found 
between PGC-1β expression status neither with number of AP sites nor with expression of 
VHL/HIF-1/C-MYC. Analysis of PGC-1β promoter methylation is ongoing. 
Discussion: Reduced mRNA expression of PGC-1α and PGC-1β was not associated with 
down-regulation of target genes, such as NRF1, TFB1M and TFB2M. POLRMT was down-
regulated in breast cancer tissues what might be implicated in decrease in mtDNA content. 
PGC-1β down-regulation was neither correlated with oxidative DNA damage status nor with 
the expression of genes of the VHL/HIF-1/C-MYC-pathway. We suspect that PGC-1β 
promoter methylation might be causal for its down-regulation. 
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Introduction 
Metabolic reprogramming, also known as the Warburg effect, is based on the shift 
from oxidative phosphorylation (OXPHOS) to aerobic glycolysis and has been suggested as 
an emerging hallmark of cancer [8]. Although the cellular and molecular mechanisms that 
promote this metabolic switch have not yet been fully elucidated, it is evident that impairment 
of OXPHOS and mitochondrial dysfunction are prominent features of tumor cells [166]. In 
this context, reduced mitochondrial DNA content has been observed in a variety of cancers 
such as breast [70], colorectal [75], gastric [76] cancers and renal cell carcinoma [77]. There 
is evidence that impairment of mitochondrial biogenesis, through the deregulation of genes 
involved in mitochondrial transcription and translation, might be crucial for reduction in 
mtDNA content in these cancers.   
Peroxisome proliferator-activated receptor - γ  coactivators PGC-1α and PGC-1β are members 
of a family of transcription co-activators that are involved in variety of  mitochondria-related 
processes, including fatty acid oxidation, heme- and mitochondrial biogenesis [79]. Both co-
activators are known to interact directly or via mediators with a wide range of transcription 
factors, such as ERR α, β, γ and nuclear respiratory factors 1 and 2 (NRF-1/-2). Downstream 
targets of NRF-1 and NRF-2 include the genes which code for key components involved in 
transcription initiation such as mitochondrial RNA polymerase (POLRMT), the mitochondrial 
transcription factor A (TFAM) and the dimethyladenosine transferases 1 and 2 (TFB1M, 
TFB2M)[167]. Thus it has been suggested that reduced expression of the PGC-1α and/or 
PGC-1β could lead to a repression or target genes and of mitochondrial biogenesis. Indeed, a 
decrease of PGC-1a expression has been found in several cancers including breast [80-81], 
colon [168] and ovarian cancer [169]. PGC-1β was also shown to be down-regulated in breast 
cancer cells [82].  
Various mechanisms have been implicated in the regulation of PGC-1α and PGC-1β. PGC-1α 
and PGC-1β are involved in the coordination of oxidative stress defence. While 
overexpression of these co-activators has been linked to decreased ROS generation [170], it is 
suspected that down-regulation of PGC-1 co-activators might lead to increased ROS 
production leading to oxidative DNA damage. Barrès et al reported that non-CpG 
hypermethylation of the PGC-1α promoter through DNMT3B leads to reduced expression of 
PGC-1α what might implicate a mechanism for decreased mitochondrial content in Type 2 
diabetes mellitus (T2DM) [171]. Additionally, PGC-1α and PGC-1β have been shown to be 
regulated in a hypoxia-dependent manner. HIF-1 mediated down-regulation of PGC-1α has 
been observed in epithelial cells under hypoxic conditions [172]. Zhang et al. found evidence 
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that HIF-1 also negatively regulates mitochondrial biogenesis via the VHL/HIF-1/C-MYC/ 
PGC-1β-pathway [173]. To better understand the mechanisms that lead to decreased mtDNA 
content in breast cancer we evaluated the regulatory network of PGC-1 co-activators and their 
target genes in breast cancer and adjacent normal tissue.  
 
Material and Methods 
Study cohort  
The tissue samples used in this study were obtained from the UMASS Cancer Center Tissue 
Bank with approval of the Institutional Review Board (IRB) of UMASS Medical School. In 
total 60 samples (paired cancerous and normal breast tissues) of 30 patients were included in 
the study. Patients' data (age, tumor size, lymph node involvement, extent of metastasis, 
estrogen receptor, progesterone receptor and Her2/neu - status) were obtained from the 
pathological reports. The study cohort (n = 30) was divided into 3 groups according to 
pathological stage: 1.) Stage 1 (n = 10); 2.) Stage 2 (n = 10) and 3.) Stage 3 (n = 10). Clinical 
characteristics are of patients are summarized in Table 1. 
 
DNA and RNA extraction 
Tissues were homogenized using a tissue homogenizer (MICCRA D-3, ART Prozess - & 
Labortechnik GmbH & Co. KG, Müllheim, Germany). DNA and RNA were extracted using 
the “High Pure PCR Template Preparation Kit” (Roche) and the RNeasy Kit (Qiagen) 
according to the manufacturer’s protocol. DNA and RNA were quantified using a Nanodrop 
spectrophotometer (Thermo scientific). DNA samples were stored at -20 ºC, RNA samples at 
-80 ºC until further use. 
 
Multiplex real-time qPCR for quantification of nDNA and mtDNA 
Simultaneous quantification of nDNA and mtDNA from tissues was performed using 
multiplex real-time qPCR and Glyceraldehyd-3-phosphat-dehydrogenase (GAPDH) and the 
mtDNA encoded ATPase 8 (MTATP 8) reference genes. The threshold cycle (Ct) values were 
obtained by the ABI Prism 7000 software. Each sample was analyzed in duplicate and one 
negative control was included in every run. The efficiency of the multiplex assay for 
amplifying both nDNA and mtDNA simultaneously was measured in our previous study 
using standard curves generated by dilution series. The content of mtDNA was calculated 
using the delta Ct (ΔCt) of an average Ct of mtDNA and nDNA (ΔCt = CtnDNA - CtmtDNA) 
in the same well as an exponent of 2 (2ΔCt) [174]. The sequences and additional information of 
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primers and probes for the GAPDH and the MTATP 8 reference genes as well as detailed 
reaction protocol is shown in Supplementary 1 (Table 1).  
 
Expression analysis 
Reverse Transcription of RNA to cDNA 
“High Capacity cDNA Reverse Transcription Kit” (Applied Biosystems) was used for reverse 
transcription of RNA to single-stranded DNA. The reverse transcription reaction was carried 
out in 20µl of total reaction volume. For reverse transcription of RNA 10µl of a 2× RT 
Mastermix was prepared as follows: 2µl 10× RT Buffer, 0.8µl  25× dNTP Mix (100mM), 2µl 
RT Random Primers, 1µl MultiScribeTM Reverse Transcriptase, 1µl RNase Inhibitor und 
3.2µl H2O. 10µl RNA template was added. The reaction was performed using a Mastercycler 
(Eppendorf) under the following conditions: a first step at 25ºC for 10 min, a second step at 
37ºC for 2 h and a third step at 85ºC for 5 min, followed by cooling to 4 ºC. 
 
Quantitative real-time PCR  for analysis of mRNA expression 
mRNA expression of selected genes was evaluated by qRT PCR. Data were normalized in 
relation to the geometric mean of two reference genes:  Beta-2-microglobulin (B2M) and 
Actin-beta (ACTB). Fold-changes in gene expression were calculated using  2-ΔΔCT cycle 
threshold method [175]. The sequences and additional information of primers as well as 
detailed reaction protocol is shown in Supplementary 1 (Table 2).  
 
ARP-Assay 
Measurement of oxidative stress induced DNA damage was done using the OxiSelect™ 
Oxidative DNA Damage Quantitation Kit (AP sites); (Cell Biolabs, CA, US). The assay was 
performed according to the manufacturer’s protocol. In brief, a known concentration of DNA 
from tissue samples was dissolved at 100µg/mL in TE-buffer. Incubation with ARP solution 
was performed for 1h at 37ºC. ARP-labeled DNA was obtained using ethanol precipitation. 
The DNA pellet was washed and dissolved in TE buffer at a concentration of 1 µg/mL. DNA 
was bound to a microwell plate, incubated with streptavidin-enzyme conjugate and 
absorbance was measured using ELISA reader (SpectraMAX 250; Molecular Devices, LLC 
US) at 450nm. Quantities of AP sites in unknown samples were determined by comparison 
with a standard curve generated from supplied DNA standard containing predetermined AP-
sites (4-40 AP sites / 105 bp).  
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Methylation analysis 
For bisulfite conversion of the target sequences, the Epitect Bisulfite Kit (QIAGEN AG, 
Basel, Switzerland) was used according to the manufacturer’s protocol. Detailed protocol for 
PCR on bisulfite converted genomic DNA and additional information of primers is shown in 
Supplementary 1 (Table 3 / Figure 1). Procedure for pyrosequencing assay for DNA 
methylation analysis has been described previously [176]. Pyrosequencing was performed on 
the PyroMark Q96 MD (QIAGEN AG, Basel, Switzerland).  
 
Statistical Analysis 
Statistical analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, USA). Normality 
distribution of the data was determined using the Shapiro-Wilk-Test. The data were not 
normally distributed. Mann-Whitney-U-Test was applied for comparing ccf nDNA and 
mtDNA levels between the three groups (Stage 1, Stage 2 and Stage 3).  Wilcoxon signed 
rank test was performed for comparing expression data. P-values ≤ 0, 05 were considered 
statistically significant. 
 
Results 
Mitochondrial DNA content in paired cancer and normal tissues 
The mtDNA content of the paired cancer and normal tissues was measured using multiplex 
real-time PCR. MtDNA content in cancer tissues was significantly lower in comparison with 
paired normal tissues (Mann-Whitney-U; P < 0.001). The comparison of mtDNA content 
between paired cancer and normal breast tissues within different stages showed no significant 
difference in mtDNA content for stage 1 breast cancer tissues (Mann-Whitney-U; n.s.); 
however stage 2 and 3 breast cancer tissues had significantly decreased mtDNA content 
compared to adjacent normal tissues (Mann-Whitney-U; P <0.05 and P < 0.05) (Figure1). 
 
Comparison of mtDNA content with clinicopathological parameters 
For the cancerous tissues the association between mtDNA content and established clinical 
parameters, including age, tumor size, lymph node involvement, extent of metastasis and the 
status of estrogen receptor (ER), progesterone receptor (PR) and Her2/neu were analyzed. No 
statistical significance between mtDNA content and any of the clinicopathological parameters 
could be found. 
 
Expression Analysis of genes involved in mitochondrial biogenesis 
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Real-time qPCR was performed to analyze mRNA expression of 7 transcription factors (PGC-
1α, PGC-1β, NRF1, NRF2, TFAM, TFB1M, TFB2M) and mitochondrial RNA polymerase 
(POLRMT). While PGC-1β was significantly down regulated (-1.0-fold), NRF1, TFB1M and 
TFB2M showed significant up-regulation (1.4-fold; 1-fold; 1.8-fold) in cancer tissues. 
POLRMT, also if not significantly, was down-regulated (-0.3-fold) (Figure 2).  
 
Assessment of hypoxic status and oxidative DNA damage  
As it has been shown that PGC-1β expression can be regulated in a hypoxia dependent 
manner and mtDNA depleted cells enhance expression of mitochondrial biogenesis genes 
such as NRF-1 and Tfam with increasing amounts of ROS, we assessed the hypoxic status 
and the status of oxidative DNA damage of cancer and normal tissue samples. HIF-1α was 
up-regulated (4.7-fold) in cancer tissues. Number of AP-sites were significantly higher in 
cancer than in normal tissues (9.56 vs. 8.69; Wilcoxon: p<0.05); what can be mainly 
attributed to stage 2 samples, the only stage exhibiting a significantly elevated number of AP-
sites in cancer in comparison to normal tissues (11.88 vs. 9.67 ; Wilcoxon: p<0.05) (Figure 3).  
 
Expression analysis of the VHL/HIF-1/C-MYC/ PGC-1β pathway 
PGC-1β down-regulation was shown to be associated with HIF-1 gain of function and loss of 
C-MYC expression in VHL deficient in renal carcinomas. In our cohort, VHL as well as HIF-
1α and C-MYC were up-regulated in cancer tissues. Inverse correlation between the 
expression levels of VHL and HIF-1α with increasing stage could be observed.  
 
Methylation analysis  
Since we found decreased expression of PGC-1β, we will perform methylation analysis using 
Pyrosequencing. Two amplicons within the promoter region are currently analyzed. Amplicon 
1 (-378 until -157) containing 20 CpGs ; amplicon 2 (-179 until +85) containing 35 CpGs.  
  
Discussion 
To get better insight in the mechanisms that lead to reduction of mtDNA content in 
breast cancer patients, we investigated the the PGC-1 regulatory network. It is believed that 
the transcriptional co-activators PGC-1α and PGC-1β are involved in the regulation of 
mitochondrial biogenesis, mainly through interaction with their target genes NRF1 and NRF2; 
which in turn are known to induce downstream targets such as POLRMT, TFAM and TFB1M 
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and TFB2M. Depletion of PGC-1α and/or PGC-1β has therefore been suspected to lead to 
impairment of mitochondrial biogenesis.  
We observed a significant decrease in mtDNA content in breast cancer tissue in 
comparison to adjacent normal tissue. Comparison of mtDNA content between different 
stages showed no significant difference between breast cancer and adjacent normal tissues for 
stage one, however significant decrease in cancer tissues could be observed for stage 2 and 3. 
Decreased mtDNA content has been found in patients suffering from various cancers such as 
renal carcinomas [77], gastric cancers [76], HCCs [177] and breast cancer [115, 178] and has 
been associated with mtDNA mutations [70, 145] and altered mRNA expression of the genes 
involved in mitochondrial biogenesis [179].     
To check whether deregulation of genes involved in mitochondrial biogenesis might 
be implicated in decrease of mtDNA content in our cohort, we firstly evaluated the expression 
status of PGC-1α and PGC-1β co-activators and their target genes. Both co-activators were 
down-regulated in breast cancer tissues, however only for PGC-1β significant down-
regulation of mRNA expression could be observed. In contrast, PGC-1β target genes NRF-1, 
TFB1M and TFB2M were significantly up-regulated. This seems quite contradictory, since it 
has been reported that PGC-1α and PGC-1β co-activate directly or via NRF1/NRF2 target 
genes like TFAM, TFB1M and TFB2M. Yet, Miranda et al. reported that in mtDNA depleted 
HeLa cells, increased concentration of reactive oxygen species (ROS) enhance the expression 
of nuclear encoded mitochondrial biogenesis genes such as NRF-1 and Tfam [180]. Correia et 
al. got similar results; they reported correlation of mtDNA depletion with up-regulation 
TFAM, TFB1M in astrocytomas and hypothesized that up-regulation of genes involved in 
mitochondrial biogenesis could be a compensatory mechanism for the decrease in mtDNA 
content [181]. Analyzing the hypoxic status and the oxidative DNA damage we found a 
significant increase in HIF-1α mRNA expression and significantly increased amount of AP 
sites in cancer tissues, suggesting that ROS levels might be higher in cancer tissues, 
supporting the aforementioned theory. However, although important target genes of PGC co-
activators were up-regulated in this cohort, POLRMT, also if not significantly, was found to 
be down-regulated in breast cancer tissues what might be implicated in decrease in mtDNA 
content in our cohort.  
With the aim to get closer insight which mechanisms lead to the decrease of PGC-1β 
mRNA expression and of mtDNA content, we assessed VHL/HIF-1/C-MYC-pathway. Zhang 
et al found evidence that PGC-1β expression is regulated via VHL/HIF-1/C-MYC-pathway in 
renal carcinoma cell lines deficient for VHL [173]. They showed that VHL loss of function 
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can lead to HIF-1 gain of function, which leads to the inhibition of C-MYC transcriptional 
activity by MXI-1 expression, resulting in loss of C-MYC-dependent PGC-1β expression and 
in reduced mitochondrial mass. Our cohort showed no VHL deficiency.  We instead found 
significant up-regulation of mRNA expression of VHL and HIF-1α and C-MYC. However, 
there was an inverse correlation between the expression levels of VHL and HIF-1α with 
increasing stage, suggesting that HIF-1α might be negatively regulated by VHL. We conclude 
that in our cohort PGC-1β is not regulated in a VHL/HIF-1/C-MYC dependent manner. 
In conclusion, in this cohort except for POLRMT, expression of all PGC target genes 
was up-regulated. The decrease in mtDNA content in the analyzed breast cancer tissues seems 
therefore not due to reduced expression of NRF-1, NRF2, TFAM or TFB1M and TFB2M. 
Yet, POLRMT is a central factor in mtDNA transcription and down-regulation of POLRMT 
might be implicated in decrease in mtDNA content. Since down-regulation of PGC-1β seems 
not to be regulated via the VHL/HIF-1/C-MYC-pathway, we are currently evaluating the 
methylation status of the PGC-1β promoter region using pyrosequencing to assess whether 
promoter methylation might play a role in the down-regulation of PGC-1β. 
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Tables and table legends 
 
Table 1. Clinical data of patients. Patient data divided into three subgroups according to                                                          
stage (stage I, stage II, stage III).  ER (Estrogen receptor); PR (Progesterone receptor);                                                                               
Her2/neu (Herceptin receptor).  
 Stage Total no. of patients 
Age (years)  
mean ± s.d. 
[range] 
Grade ER     
positive 
PR     
positive 
Her2/neu 
positive 1 2 3 
1 10 59.8 ± 18.4  [36-94]     2 6 2 10 6 0 
2 10 62.6 ± 10.5   [51-82] 0 6 4 9 7 0 
3 10 59.7 ± 12.6   [43-82] 1 4 5 7 4 1 
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Figures and figure legends 
 
 
Figure 1. Boxplots for comparison of mtDNA content for IDC tissues (n=30) and adjacent 
normal tissues (n=30). A. Comparison of mtDNA content between cancer and normal breast 
tissues. B. Comparison of mtDNA content between cancer and normal breast tissues within 
different stages. (*significant correlation: Mann-Whitney-U).  
 
Figure 2. A. Real-time PCR quantification of mRNA expression for genes involved in 
mitochondrial biogenesis (PGC-1α, PGC-1β, TFAM, NRF1, NRF2, TFB1M, TFB2M, 
POLRMT) for IDC tissues (n=30) and adjacent normal tissues (n=30); B. Real-time PCR 
quantification of total and stage related (stages1-3) PGC-1β mRNA expression for IDC 
tissues (n=30) and adjacent normal tissues (n=30). mRNA expression normalized to 
B2M/ACTB; given as fold-change ± SEM; * indicates significant difference from adjacent 
normal tissues; P<0.05 (Wilcoxon signed rank test). 
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Figure 3. Oxidative DNA damage quantitation by ARP-Assay for IDC tissues (n=30) and 
adjacent normal tissues (n=30). Number of AP sites in cancerous and adjacent normal tissues 
per 106 bp. * indicates significant difference from adjacent normal tissues; P<0.05 (Wilcoxon 
signed rank test). 
 
 
 
 
Figure 4. Real-time PCR quantification of mRNA expression for HIF-1α, VHL and C-MYC 
for IDC tissues (n=30) and adjacent normal tissues (n=30); normalized to B2M/ACTB; given 
as fold-change ± SEM. A. Total fold-change. B. Fold-change according to different stages. * 
indicates significant difference from adjacent normal tissues; P<0.05 (Wilcoxon signed rank 
test). 
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Supplementary  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 1. Real-time PCR primers for nDNA/mtDNA quantification. 
Gene Gene ID Primer ID Primer sequence 5`→3` Length (bp) Tm 
Amplicon 
lenght (bp) 
GAPDH 2597 
GAPDH_F CCCCACACACATGCACTTACC 21 
60 97 GAPDH_R CCTAGTCCCAGGGCTTTGATT 21 
Probe MGB–TAGGAAGGACAGGCAAC–FAM 17 
MTATP8 4509 
MTATP8_F AATATTAAACACAAACTACCACCTACC 27 
60 79 MTATP8_R TGGTTCTCAGGGTTTGTTATA 21 
Probe FAM-CCTCACCAAAGCCCATA-MGB 17 
      
For the simultaneous quantification of nDNA and mtDNA the mulitplex real-time PCR was carried out in 25 μl 
of total reaction volume containing 7 μl H2O, 12.5 μl TaqMan® Universal PCR Master Mix (Applied 
Biosystems, Branchburg, New Jersey, USA), 0.75 μl of each of the above mentioned 10 μM primers 
(Microsynth, Balgach, Switzerland), 1 μl of a 5 μM FAM-labeled MTATP 8-probe and 0.5 μl of a 5 μM VIC-
labeled GAPDH-probe (both probes from Applied Biosystems, Rotkreuz, Switzerland). For each reaction 1 μl 
of template was added. The real-time PCR was performed using ABI PRISM 7000 sequence detection system 
(Applied Biosystems) under the following conditions: an initiation step for 2 minutes at 50°C is followed by a 
first denaturation for 10 minutes at 95°C and a further step consisting of 40 cycles of 15 seconds at 95°C and 1 
minute at 60°C.                                        
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Table 2. Real-time PCR primers for mRNA expression. 
Gene Gene ID Primer ID Primer sequence 5`→3` Primer length (bp) Tm 
Amplicon 
lenght 
(bp) 
HIF-1α 3091 
HIF1_F TGCTCATCAGTTGCCACTTC 20 
60 178 
HIF1_R AAAACCATCCAAGGCTTTCA 20 
C-MYC 4609 
C-MYC_F TCCTCGGATTCTCTGCTCTC 20 
60 180 
C-MYC_R CTCTGACCTTTTGCCAGGAG 20 
NRF-1 4899 
NRF1_F AGAAAGCTGCAAGCCCATCT 20 
60 193 
NRF1_R CTGTGTTTGCGTTTGCTGAT 20 
NRF-2 2551 
NRF-2_F AAGTGACAAGATGGGCTGCT 20 
60 171 
NRF-2_R CCGAAATGTTGAGTGTGGTG 20 
PGC-1α 
(PPARGC1A) 10891 
PGC-1α_F CACCAGCCAACACTCAGCTA 20 
60 220 
PGC-1α_R GTGTGAGGAGGGTCATCGTT 20 
PGC-1β 
(PPARGC1A) 133522 
PGC-1β_F ATGACTCCGAGCTCTTCCAG 20 
60 152 
PGC-1β_R  CGAAGCTGAGGTGCATGATA 20 
POLRMT 5442 
POLRMT_F CTGCAGTGCCTCTTTGAGAA 20 
60 150 
POLRMT_R CAGTGCTTTCTCCCATTGGT 20 
TFAM 7019 
TFAM_F 
TACCGAGGTGGTTTTCATCTG 21 60 150 
TFAM_R AACGCTGGGCAATTCTTCTA 20 
TFB1M 51106 
TFB1M_F AGCACCTGGGAAACTGAGAA 20 
60 206 
TFB1M_R TGCCATAAACAAAAGGTCCA 20 
TFB2M 64216 
TFB2M_F CGAGTGATCCACTGTGACTTCT 22 
60 182 
TFB2M_R CAAAGTGCCCTTTTCTCACC 20 
VHL 7428 
VHL_F TCTCAATGTTGACGGACAGC 20 
60 165 
VHL_R ACATTTGGGTGGTCTTCCAG 20 
B2M * 567 
B2M_F GTGCTCGCGCTACTCTCTCT 20 
60 150 
B2M_R GTCAACTTCAATGTCGGATGG 21 
ACTB * 60 
ACTB_F CGTCTTCCCCTCCATCGT 18 
60 181 
ACTB_R GGTGTGGTGCCAGATTTTCT 20 
 
The real-time PCR was carried out in a 12.5 µl total volume, containing 4.5µl H2O, 6.2µl PCR SybrGreen 
Mastermix (Applied Biosystems, Branchburg, New Jersey, USA), 0.4µl of each primer (10µM) and 1µl of 
cDNA template. The real-time PCR was performed using ABI PRISM 7000 sequence detection system 
(Applied Biosystems) under the following conditions: an initiation step for 2 minutes at 50°C is followed 
by a first denaturation for 10 minutes at 95°C and a further step consisting of 40 cycles of 15 seconds at 
95°C and 1 minute at 60°C.                                        
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Table 3. PGC-1β primers for PCR of the two amplicons on bisulfite-converted genomic DNA.   
Gene Primer Sequence (5`→3`) Length (bp) Tm 
Product 
size (bp) Start/End 
PPARGC1B 
PPARGC1B_A1_F AGTTGTGTAGAAGAAGTAGGTTGT 24 59 221 -378 /       -157 PPARGC1B_A1_R RAAAATCRCTCACCCACT 19 
PPARGC1B_A2_F GAAAGTGGGTGAGYGATTT 19 61 264 -179 /  +85 PPARGC1B_A2_R AAAAAAAAAAAAAACTCTTCRTCC 24 
       
The PCR on bisulfite-converted genomic DNA was carried out in 50µl total reaction volume containing 20 ng 
DNA, 1pmol of each primer, 200μM dNTP, 0.2 U Hot Start Taq DNA polymerase, 1.5 mM MgCl2 and 10* PCR 
buffer.The reaction was performed under the following conditions: an initial denaturation at 94ºC for 10 min, 
followed by 40 cycles of denaturation at 94ºC for 20s, annealing at 56 ºC for 30s and primer extension at 72°C for 
1 min.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of the PPARGC1B gene promoter region. The 
transcription start side is indicated by one-sided arrow (+1); CpG sites are shown as red 
lines.; two-sided arrows represent the two amplicons (A1, A2) analyzed by 
pyrosequencing. 
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4. SUMMARY AND FINAL CONCLUSION 
 
Breast cancer remains the most common cancer among women worldwide. Yet, during the 
past decades a reduction in breast cancer mortality could be observed in westernized 
countries, mainly attributable to earlier diagnosis due to regular screening and frequent use of 
systemic adjuvant treatment [1-3]. Although standard screening methods such as clinical 
breast examination (CBE) and Full-Field Digital Mammography (FFDM) are non-invasive 
itself, their sensitivity and specificity is limited and they still require biopsy proof after 
suspicion. Circulating cell-free nucleic acids represents a new generation of markers with the 
advantage that both, quantitative as well as qualitative alterations of ccf-nucleic acids are 
potentially applicable as non-invasive biomarker.  
 
In the first part of this study, we investigated quantitative alterations of ccf-nDNA and 
ccf-mtDNA in the plasma of breast cancer patients and healthy controls to evaluate the 
applicability of ccf-nuclear and mitochondrial DNA as biomarker for distinguishing between 
different study groups (malignant, benign, and healthy). We found increased levels of ccf-
nDNA in the cancer group in comparison with the benign tumor and the healthy control 
groups. In contrast ccf-mtDNA was found to be significantly lower in the two tumor-groups 
(benign and malignant) in comparison with the healthy control group. This phenomenon has 
been reported frequently, however the underlying mechanisms leading to an increase of ccf-
nDNA and to a decrease of ccf-mtDNA in cancer patients have not been elucidated. It is 
speculated that high cellular turn-over at tumor site might lead to an increased shedding of 
tumor-derived ccf-nucleic acids into the circulation [4]. However, this would not explain the 
decreased levels in ccf-mtDNA. A decrease in mtDNA has not only been observed in the 
circulation but also in cancer cells themselves. It has been suspected that mtDNA mutations 
and deregulation of genes involved in mitochondrial biogenesis might be causal [5-7].  While 
using nDNA levels we could distinguish between breast cancer patients and healthy controls 
with a sensititvity of 81% and a specificity of 69%, mtDNA levels enabled a discrimination 
between breast tumor patients (cancerous and benign) and healthy controls with a sensititvity 
of 53% and a specificity of 87%. Altogether this suggests that although ccf-nDNA as well as 
mtDNA levels could be used for discrimination between the study groups, the limited 
sensitivity and specificity of the approach doesn’t allow for clinical application. Limited 
sensitivity and specificity is a well known problem using quantitative alterations of ccf-
nucleic acids as biomarker. Other groups, using ccf-nDNA levels as potential 
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diagnostic/predictive marker for different cancer types, got similar results. In non-small cell 
carcinoma of the lung a differentiation between 79 healthy individuals and 151 patients could 
be performed with a sensitivity of 85.8 % and a specificity of 46.8 % using 2 ng /mL as cut-
off value [8]. Recently, Kamat et al. determined the role of pre-operative total plasma ccf-
DNA levels in predicting clinical outcome in patients with ovarian cancer. Diagnosis of 
invasive ovarian cancer yielded a sensitivity of 87% and specificity of 87% with a cut-off 
value of 4,500 GE/ml. Interestingly, the sensitivity and specificity of predicting malignancy in 
their cohort using CA125 (cutoff of ≥ 35 IU/mL) was comparable with 89% and 77%, 
respectively [9]. Although recently researchers tried to develop new state of the art 
approaches for the quantification of ccf-nucleic acids no successful improvement towards 
increased sensitivity and specificity could be achieved. We showed that ccf-nDNA and 
mtDNA has limitations as a biomarker for early diagnosis of breast cancer. Further studies 
might identify specific patient cohorts in which such alterations can serve as a prognostic and 
predictiv biormarker for breast cancer. To this end, it is necessary to find cancer-specific 
qualitative alterations which provide high enough sensitivity and specificity. Such alterations 
could be applied primarily as diagnostic biomarker to non-invasively screen ccf-DNA.  
 
To identify cancer-linked genes, Sjöblom et al. and Wood et al. performed a genome-
wide mutation screening in human breast and colorectal cancer. Within their study they tested 
more than 13,032 human protein-coding genes in human breast and colorectal cancer. By 
using very stringent criteria, 189 genes were found to be mutated at a significant frequency in 
those cancers, which they called candidate cancer genes (CAN-genes) [10, 11].  We evaluated 
the value of these CAN-gene mutations as biomarkers for breast cancer. Using MALDI-TOF 
MS 40-plex assay, we checked 21 CAN-genes and 40 loci in 6 breast cancer cell lines and in 
tissue samples of 19 breast cancer patients and 55 healthy controls .The mutation rate of the 
analyzed loci in our sample cohort was very low. Only a single breast cancer tissue sample 
showed heterozygosity at locus c.5834GA within the ZFYVE26 gene (Zinc finger FYVE 
domain-containing gene 26). Sjöblom et al./Wood et al. already showed that the vast majority 
of genes are mutated at very low frequency and therefore rarely detectable. We suppose that a 
low mutation frequency of our loci analyzed in this study might be one reason we couldn’t 
detect a huge amount of mutations in our cohort.  A study by Balakrishnan et al., evaluated 
whether the CAN-genes are universal for all cancer types or cancer type specific. They 
analyzed the mutational profiles of 19 CAN-genes in the highly aggressive tumors: 
glioblastoma, melanoma, and pancreatic carcinoma. They mainly found novel somatic 
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mutations in a subset of genes. None of the somatic mutations described by Sjöblom et al. 
were found in their analyses of glioblastoma multiforme, melanoma, and PDAC samples [12]. 
These results implicate that each type of tumor might have its own CAN-gene signature and 
only a few of the CAN-genes are maybe shared by different tumor types. The value of CAN-
gene mutations found by Sjöblom et al. / Wood et al. could therefore be restricted to the 
cancer type they were detected in and might therefore only usable as cancer type specific 
marker. In general, the interpretation of genome-wide mutation screenings and the search for 
cancer specific qualitative nuclear DNA alterations seems to be a tricky undertaking. First of 
all screening approaches usually yield an enormous amount of candidates, making it difficult 
to select key alterations for detailed evaluation. In addition, it is known that besides inter-
variations between distinct cancer types there are enormous intra-variation within the same 
cancer type, implying that carcinogenesis is also partly be individually determined, what 
suggests a probable need for personalized approaches.  
Compared to nDNA, the analysis of mtDNA mutations has some advantages such as 
higher mtDNA copy numbers and higher mutation rate. We used sanger sequencing with the 
aim to determine somatic mtDNA mutations within the D-loop region in breast cancer tissues 
and to evaluate whether it is possible to detect these mutations in the matched plasma 
samples. We therefore sequenced the two hypervariable regions HVR1 and HVR2, which are 
located in the D-Loop and are known as mutational hotspots in ten paired tissues and plasma 
samples from breast cancer patients. MtDNA mutations were found in all patients’ samples. A 
total of 85 germline mutations and of 42 somatic mutations in the D-loop region were found. 
MtDNa mutations seem to be a more promising biomarker than nDNA mutations for several 
reasons. Firstly, mtDNA is highly abundant in every cell making it easily accessible. The 
mutation frequency is known to be much higher what was also evident in our study and the 
homoplasmic nature of mtDNA makes it an ideal molecular marker [13, 14]. Using sanger 
sequencing we could not find mutant mtDNA in plasma samples. This might be due to the 
fact that the amount of circulating mutant mtDNA is tiny in comparison to background wild-
type mtDNA. At the moment, highly sensitive applications that enable a more sensitive 
discrimination between circulating mutant gene fragments and normal circulating DNA 
fragments are on the way [15, 16].  
 
In general, limited sensitivity and specificity can be considered as the bottleneck of using 
quantitative as well as qualitative alterations as marker. In the past few years, researchers tried 
to overcome that problem working on methodological improvements and applying state of the 
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art technologies for detecting and the analyzing quantitative and qualitative alterations of ccf-
nucleic acids [15, 17-19]. However, even these measures could not achieve a designated 
outcome. A first step towards overcoming the problem of limited sensitivity and specificity 
should be therefore the use of multi-marker approaches. Flamini et al. recently evaluated a 
combined use of cell-free DNA and carcinoembryonic antigen (CEA) serum levels for 
diagnosis of colorectal cancer. ROC curve analysis using a combination of CEA and cell-free 
DNA levels showed a higher diagnostic capacity than that of markers considered singly [20]. 
In another multi-marker study, Sunami et al. assessed serum prostate specific antigen (PSA) 
levels in combination with ccf-DNA for allelic imbalance of 6 genome microsatellites and 
methylation status of RASSF1, RARB2, and GSTP1. By combining the 2 assays, the number 
of prostate cancer patients positive for  methylated or LOH marker increased to 63%. 
Combination of DNA and PSA assays gave 89% sensitivity. 
 
In our first study, we found decreased mtDNA content in tumor patients in comparison 
with healthy controls. A phenomenon that has been frequently reported in breast cancer [7, 
21, 22]. Warburg found that malignant transformation is often accompanied by a shift from 
oxidative phosphorylation (OXPHOS) to aerobic glycolysis and he hypothesized that this 
could be the result of mitochondrial dysfunction [23]. Events that have been suspected to lead 
to mitochondrial dysfunction include among others mtDNA mutations and altered expression 
of genes involved in mitochondrial biogenesis.  
In a first part we therefore investigated the inter-genomic crosstalk between mtDNA 
alterations (mtDNA content and mutations) and methylation status of 22 breast cancer 
candidate genes. Although we found significantly reduced mtDNA content in cancerous 
tissues compared to normal paired tissues, we couldn`t find a correlation with neither somatic 
mtDNA mutations nor with clinicopathological parameters. Correlation analyzes revealed 
inverse correlation of hypermethylated TP21 and positive correlation of hypomethylated 
BRCA2 with mtDNA content as well as inverse correlation of hypomethylated progesterone 
receptor and positive correlation of hypermethylated GSTP1 with mtDNA mutations. A 
correlation between mtDNA mutations and a decrease in mtDNA content has been reported in 
several studies. Yu et al. observed that esophageal tumors harboring mutations in 
displacement (D)-loop region, particularly at the polycytidine stretch or close to the 
replication origins of the heavy-strand, had a significantly lower copy number of mtDNA than 
the ones without D-loop alterations. Lee et al. on the one hand showed that mtDNA copy 
number of HCC was significantly decreased in 60.5% of the patients with hepatoma, 
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especially in those with somatic mutation(s) in the D-loop of mtDNA; but interestingly, they 
found that 42.9% (6/14) of the HCCs without mutation in the D-loop had a reduced copy 
number of mtDNA, indicating that other unidentified factors involved in mitochondrial 
biogenesis might be defective in the tumor. Yet, various other groups couldn’t find an 
association between somatic mtDNA mutations and reduced mtDNA content [24]. Since 
mtDNA has been shown to be highly mutated in cancer, it is difficult to assess which 
mutations are the causing mutations, leading to a decrease in mtDNA content. Unfortunately 
until now there are very few studies that analyzed the intergenomic cross-talk between nDNA 
methylation and mtDNA alterations, making it difficult to see our results in a general context. 
There is evidence that impairment of mitochondrial biogenesis, through the deregulation 
of genes involved in mitochondrial transcription and translation, might be causal for reduction 
in mtDNA content. Analysis of the regulatory network of PGC-1 co-activators and their target 
genes in 30 paired breast cancer and adjacent normal tissue samples revealed down-regulation 
of PGC-1α and PGC-1β. Reduced mRNA expression of PGC-1α and PGC-1β was not 
associated with down-regulation of target genes, such as NRF1, TFB1M and TFB2M. 
POLRMT was down-regulated in breast cancer tissues what might be implicated in decrease 
in mtDNA content. PGC-1β down-regulation was neither correlated with oxidative DNA 
damage status nor with the expression of genes of the VHL/HIF-1/C-MYC-pathway. Future 
analyzes of the methlytion status of the PGC-1β promoter region might clarify if methylation 
is involved in down-regulation of PGC-1β in cancer patients. Until this point, we could 
confirm the results of other groups, observing reduced mRNA expression of PGC-1α and 
PGC-1β in breast cancer tissues.  Although we found several PGC-1 target genes upregulated, 
downregulation of POLRMT might be implicated in decrease of mtDNA in our cohort. Our 
ongoing studies will provide answers to these open questions. 
 
To conclude, although during the last decade a boost for research on ccf-nucleic acids 
has led to increased knowledge about their release mechanisms, biological characteristics, 
physiological and pathophysiological behaviour, the conclusions drawn from the tremendous 
amount of studies are rather vague and many questions are still unanswered. Firstly, one can 
not ignore that the varying results obtained by different studies - for quantitative as well as for 
qualitative alterations - are a general problem in the research on ccf-nucleic acids. Therefore a 
major issue that should be tackled within the coming years is the standardization of assays in 
regard to sampling procedures (blood collection, processing, storage), isolation methods 
(commercial kits, laboratory protocols), the use of assay platforms (PCR, BEAMing, massive 
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parallel sequencing) and data analyzes [25]. Another major problem concerning quantitative 
as well as qualitative ccf-nucleic acid alterations is their limited specificity and sensitivity. 
The lack of suitable qualitative alterations as marker might be solved in recent years 
considering the technological advances in the development of high-throughput technologies.  
However, until the detection of more sensitive qualitative markers, one of the primary aims of 
future research should be the development of multi-marker assays to overcome the obstacle of 
limited sensitivity and specificity. In addition there is a need for basic research to improve the 
understanding of molecular mechanisms that underlie quantitative and qualitative alterations 
in physiological as well as in pathophysiological conditions. Summing up, investment in basic 
research in combination with standardization, use of state of the art technologies and the 
application of multi-marker approaches could lead to the development of more sensitive and 
specific methods and finally to the detection and clinical application of new non-invasive 
biomarkers for cancer management.  
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